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Friedreich ataxia (FRDA) is a neurodegenerative disorder that is inherited in an 
autosomal recessive pattern. The most common FRDA mutation is hyperexpansion 
of a GAA triplet repeat sequence in the first intron of the affected gene, frataxin 
(FXN), resulting in decreased frataxin protein expression. The hyperexpanded GAA 
repeats can adopt unusual DNA structures and induce aberrant epigenetic changes 
leading to heterochromatin mediated gene silencing. Several epigenetic changes, 
including increased levels of DNA methylation, histone modifications, repressive 
chromatin formation and elevated levels of non-coding RNA have been reported in 
FRDA. It has been reported that a novel FXN antisense transcript (FAST-1), is 
present at higher levels in FRDA patient-derived fibroblasts and its overexpression is 
associated with the depletion of CTCF, a chromatin insulator protein, and 
heterochromatin formation involving the critical +1 nucleosome. Previously, 
characteristics of FAST-1 were investigated in our lab and a full-length FAST-1 
transcript containing a poly (A) tail was identified. To investigate any possible effects 
of FAST-1 on FXN expression, I first overexpressed this FAST-1 transcript in three 
different non-FRDA cell lines and a consistent decrease of FXN expression was 
observed in each cell type compared to control cells. I also identified that FAST-1 
copy number is positively correlated with increased FAST-1 expression, which in turn 
is negatively correlated with FXN expression in FAST-1 overexpressing cells. 
Additionally, we found that FAST-1 overexpression is associated with increased 
levels of DNA methylation at CpG sites U6 and U11 of the FXN upstream GAA 
repeat region, together with CTCF depletion and heterochromatin formation at the 
5′UTR of the FXN gene. To further investigate the role of FAST-1 in FXN gene 




expression in FRDA fibroblast cells. I found that knocking down FAST-1 increases 
FXN expression, but not to the level of control cells. Lastly, I investigated the pattern 
of FAST-1 expression and histone modifications at the FXN transgene in our new 
FRDA mouse model, designated YG8LR. The YG8LR mice showed decreased 
levels of FXN expression and H3K9ac and increased levels of FAST-1 expression 
and H3K9me3. Our data suggest that since FAST-1 is associated with FXN gene 
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1.1 Friedreich ataxia 
Friedreich ataxia (FRDA, OMIM #229300), the most common inherited ataxia, is an 
autosomal recessive neurodegenerative disorder. The first symptoms, which are limb 
and gait ataxia and loss of tendon reflexes in the lower limbs, appear before the age 
of 25, and then patients develop dysarthria, loss of ability to walk and loss of 
sensation. Scoliosis is also present in most case of FRDA and is clearly progressive. 
There is no treatment for FRDA and patients mostly die of progressive hypertrophic 
cardiomyopathy in their early adulthood. FRDA is a rare genetic disorder with an 
estimated prevalence of one case per 50,000 individuals. It is commonly caused by 
hyperexpansion of a GAA triplet repeat in the first intron of both copies of the FXN 
gene (Campuzano et al., 1996). Only 5% of patients are heterozygotes for a point 
mutation in one allele and a GAA expansion on the other allele (Pandolfo, 2002; 
Gellera et al., 2007). Normal individuals have up to ~40 triplets, whereas in FRDA 
patients the number of GAA repeat can be from 70 to 1700 (Dürr et al., 1996; 
Pandolfo, 2002). The GAA repeat size determines the level of residual frataxin and is 
directly correlated to an earlier age of onset and more rapid rate of disease 
progression. The GAA repeat expansion causes a transcriptional defect of the FXN 
gene, and reduced levels of frataxin, a 210 amino acid mitochondrial protein, results 
in mitochondrial dysfunction and oxidative damage (Campuzano et al., 1997; 
Pandolfo, 2008). 
1.2 FXN gene structure and expression 
In 1988 Chamberlain et al carried out genetic linkage analysis on 22 families with 
three or more affected siblings and detected that the mutation causing FRDA occurs 
in chromosome 9 (Chamberlain et al., 1988). Further linkage studies on about 120 
affected families localised the disease locus to chromosome 9q13-9q21 (Hanauer et 
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al., 1990). In 1996 the FRDA locus was narrowed down to 9q13 and a gene called 
X25 was identified in that region (Campuzano et al., 1996). The gene, initially called 
X25 and later changed to FRDA, is now known as FXN. Using direct complementary 
DNA (cDNA) selection and exon amplification, the coding sequences of FXN gene 
were identified. An inverse polymerase chain reaction (PCR) approach was used to 
identify the intronic sequence flanking the known coding regions and therefore, the 
FXN gene structure was determined (Campuzano et al., 1996). Screening the FXN 
gene for mutations in FRDA patients revealed that an expanded trinucleotide repeats 
(GAA) within the first intron of FXN gene accounted for about 98% of FRDA cases. 
The FXN gene is composed of seven exons spanning 95 kb of genomic DNA. Exons 
1 to 5a produce the major transcript, a 1.3kb mRNA that encodes a 210-amino acid 
protein, called frataxin. Since the exon 5b has an in-frame stop codon, alternative 
splicing can give a rise to a 171-amino acid coding transcript (Campuzano et al., 
1996). Exon 6 is entirely noncoding. Two major transcription start sites, TSS1 and 
TSS2, were identified at 221bp and 62bp upstream of the ORF, respectively. Greene 
et al. revealed that a region located between -221 and -121 bases upstream of the 
ATG translation start site plays a crucial role in regulation of the FXN promoter 
(Greene et al., 2005). No TATA box element was apparent in this region and the 
Initiator (Inr)-like elements associated with the TSS1 did not affect the FXN gene 
expression (Kumari et al., 2011). Two transcription factors, serum response factor 
(SRF) and transcription factor activator protein 2 (TFAP2), were found to bind 
directly to this region and mutagenesis of either SRF or TFAPA2 binding sites 
significantly decreased FXN promoter activity (Li et al., 2010). The FXN gene is 
expressed in all cells but it has variable tissue-specific levels of expression. 
Generally, in tissues with high metabolic rate, the frataxin expression is high. FXN is 
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significantly expressed in heart and spinal cord, intermediately in liver, skeletal 
muscle, and pancreas and minimally in other tissues (Koutnikova et al., 1997). In the 
central nervous system (CNS), the highest frataxin expression has been detected in 
dorsal root ganglia (DRG), much lower in cerebellum and lowest in cerebellar cortex 
(Delatycki et al., 2000). The frataxin mRNA level in FRDA patients is varied in an 
inverse GAA length-dependent manner. Depending on the GAA repeat size, FRDA 
patients can have 13%-30% of the normal frataxin mRNA levels (Pianese et al., 
2004; Bidichandani et al., 1998). 
1.3 Frataxin protein 
Frataxin (FXN) is a nuclear-encoded 210 amino acid protein which is produced in the 
cytosol as a precursor form. It contains N-terminus mitochondrial targeting peptides 
that direct the precursor to mitochondria matrix. Data obtained from transfection of 
mammalian cells with human FXN in GFP-expression localised frataxin to the 
mitochondria (Babcock et al., 1997). Following import of the precursor into the 
mitochondria, mitochondrial processing peptidase (MPP) proteolytically removes the 
N-terminal sequence in two sequential steps and generates the 14.5 kDa functional 
mature frataxin encoded by amino acids 81-210 (m81-FXN) (Campuzano et al., 1996; 
Gibson et al., 1996; Cavadini et al., 2000; Schmucker et al., 2008). Recently it has 
been shown that before the mitochondrial import, RNF125 as the E3 ligase enzyme 
ubiquitinates a significant amount of frataxin precursor and targets them to 
ubiquitin/proteasome degradation. Preventing frataxin degradation is considered as 
a potential therapeutic approach for FRDA (Rufini et al., 2011; Benini et al., 2017). 
Solution and crystal structure of mature frataxin revealed that frataxin is a compact, 
globular protein containing two α-helices, a middle β sheet region and a C terminal 
coil. Frataxin is characterized by a unique fold which allows two terminal α-helices to 
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frame a platform composed of five antiparallel β strands. C terminus of β5 with β6 
and β7 form a smaller β sheet which interacts with the planes and confers an overall 
compact α-β sandwich structure (Dhe-Paganon et al., 2000; Musco et al., 2000; 
Bencze et al., 2006). Alignment of human frataxin and CyaY sequences revealed 
that FXN C-terminal region is evolutionary highly conserved portion of the protein, 
which all missense mutation found so far in individuals with heterozygous FRDA 
affect this domain. This observation suggests that C-terminus is essential for folding 
and function of FXN. Mutation affecting N-terminal region of FXN causes an atypical 
and milder FRDA phenotype in which patients show slower disease progression 
(Figure 1.1) (Cossée et al., 1999; De Michele et al., 2000; Musco et al., 2000). 
 
1.3.1 Frataxin and iron homeostasis  
Presence of frataxin in a wide range of species from bacteria to humans 
demonstrates that it is an evolutionary conserved protein. Although its exact 
molecular function is unclear at the present, early embryonic death in nullizygous 
Fxn mice suggests that frataxin is essential for emberyonic development (Cossée et 
al., 2000). It is generally accepted that FXN is involved in iron homeostasis and 
assembly of iron-sulphur (Fe-S) clusters (Gibson et al., 1996; Adinolfi et al., 2009; 
Pastore and Puccio, 2013). Babcock et al. (1997) provided the first insight into the 
Figure 1.1: Structure of frataxin.  
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role of FXN. They reported that deletion of Yfh1 (yeast FXN homologue gene) results 
in accumulation of mitochondrial iron and hypersensitivity to oxidative stress 
(Babcock et al., 1997). Further studies revealed that reintroduction of Yfh1 leads to 
rapid export of accumulated iron from the mitochondria into the cytosol. This 
observation indicates a regulatory role for frataxin homologue Yfh1p in maintaining 
mitochondrial iron homeostasis (Radisky et al., 1999). There are several lines of 
evidence indicating that FXN is involved in the assembly of iron-sulphur (Fe-S) 
clusters. It has been reported that FXN deficiency results in reduced activity of Fe-S 
proteins such as the Krebs cycle enzyme aconitase. Deficient activities of complexes 
I–III of the respiratory chain and of the aconitases (Puccio et al., 2001) in FRDA 
mouse models and Δyfh1 yeast and FRDA patients (Rotig et al., 1997) have been 
detected (Pandolfo and Hausmann, 2013). Puccio et al. ( 2001) generated two 
different tissue-specific knock-out mouse models and they reported a 77%-87% 
complex II deficiency and a 70-74% aconitase deficiency without noticeable 
mitochondrial iron accumulation in both models (Puccio et al., 2001). Interestingly, it 
has been reported that Fxn deficient mice show 50% of Fe-S enzyme activity at 4 
weeks age (Seznec et al., 2004). These results propose an important but not 
essential role for FXN in Fe-S cluster biosynthesis. 
1.3.2 Oxidative stress 
Due to impaired mitochondrial iron efflux in FRDA, iron accumulates in mitochondria. 
This excess iron, which is primarily ferrous Fe [II], leads to increased Fenton-
mediated toxic free radical (hydroxyl radicals OH●) production and consequently 
increased oxidative stress. OH● is a highly toxic and can damage any biological 
macromolecule such as mitochondrial DNA and consequently result in cell death. 
Several studies were consistent with the idea that iron accumulation leads to 
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oxidative stress in FRDA. Measuring the concentration of 8 hydroxy 2’ 
deoxyguanosine (8OH2’dG; a marker of oxidative DNA damage) in FRDA patients 
(Schulz et al., 2000), serum malondialdehyde (MDA; a marker of lipid peroxidation) 
in FRDA mouse model (Al-Mahdawi et al., 2006) and FRDA patients (Bradley et al., 
2004) showed an increase in the level of these oxidative parameters. However, 
results from other studies questioned the role of oxidative stress in FRDA (Armstrong 
et al., 2010). Data from conditional knock-out mouse models revealed that iron 
accumulates in mitochondria in a time-dependent manner and it occurs after 
inactivation of Fe-S dependent enzymes (Puccio et al., 2001). Moreover, it has been 
demonstrated that complete Fxn deficiency does not induce oxidative stress in 
neuronal tissues of an FRDA mouse model (Seznec et al., 2005). Conflicting results 
obtained from different studies point out the need of further research on contribution 
of iron accumulation and oxidative damage in FRDA.  
1.4 GAA repeat expansion in FRDA 
Campuzano et al. (1997) showed that compared to normal individuals, the intron 1 in 
FRDA patients is larger and it contains pure GAA repeat expansion. 96% of FRDA 
chromosome abnormality is due to the homozygous expansion of GAA repeat within 
the first intron of the FXN gene. The remaining cases are heterozygous for GAA 
repeat expansion on one allele and a point mutation on the other (Campuzano et al., 
1996). A normal sequence carries ~6-36 triplet repeats, whereas affected individuals 
have approximately 70 up to 1700 triplets, most commonly 600–900 GAA triplets on 
both alleles of the FXN gene (Pandolfo, 2009; Cossee et al., 1997; Bidichandani et 
al., 1998). Investigating the GAA repeat size in normal chromosomes revealed 
length polymorphism in normal alleles. 83% of normal alleles carry 6-10 GAA units, 
which are named small normal (SN) and 17% of them contain 12-36 triplets and form 
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large normal group (LN) (Montermini et al., 1997; Pandolfo, 1998; Monticelli et al., 
2004). Like all simple-sequence repeats, the basic polymorphism-generating 
mechanism can be accounted for size heterogeneity in normal alleles. Based on this 
mechanism, during DNA replication, occasional ‘stuttering’ of DNA polymerase can 
result in size heterogeneity in normal alleles (Montermini et al., 1997). Due to the 
slippage during replication of repetitive sequences, the new strand mispairs with the 
template strand, creating an unpaired repeat loop. After a second round of 
replication this ‘slip out’ can give a rise to expanded repeat (Mirkin, 2006). Probably 
a rare or singular event caused the jump from a small normal to large normal group. 
Several studies have demonstrated that the long normal alleles are interrupted by 
hexa-nucleotide repeats (GAGGAA), which prevent these large normal alleles from 
further expanding and forming pathological expanded alleles. It has been directly 
observed that uninterrupted long normal alleles, named as permutations, can 
undergo large expansion into an allele containing >650 triplets (Montermini et al., 
1997; Patel and Isaya, 2001; Holloway et al., 2011).  
1.4.1 Instability of GAA expanded repeats 
The pathological expanded allele size is highly variable and it shows both somatic 
(mitotic) and intergenerational instability. That means that the GAA repeat size 
continues to differ within the tissues and across the generations (Pianese et al., 
1997). Several studies have demonstrated that parental gender plays an important 
role in GAA repeat size variation. It has been observed that in maternal transmission 
both contraction and expansion of the GAA allele can be detected, whereas following 
paternal transmission there is a tendency for the GAA repeat to contract (Pianese et 
al., 1997; De Michele et al., 1998). In addition, as the parents age, the contractions 
in the paternal transmission and the expansions in the maternal transmission are 
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more evident (Kaytor et al., 1997; De Michele et al., 1998). It has been observed that 
sibs with same parental mutant chromosome show different repeat lengths. It has 
been documented that somatic mosaicism in FRDA patients is length-dependent, 
tissue-specific and age-dependent (Clark et al., 2007). Mitotic GAA instability shows 
a strong tendency to contract. The expanded GAA alleles in peripheral leukocytes 
revert to normal size, whereas in the DRG, a predilection for further expansion has 
been detected (Sharma et al., 2002). In addition, alleles containing less than 25 
triplets are completely stable and when the number of triplets exceeds 44, somatic 
instability can be detected (Sharma et al., 2002; Clark et al., 2007). Comparing 
somatic instability in a FRDA 18-week foetus and a 24-year-old FRDA patient, both 
homozygous with the same E allele sizes, revealed that foetal tissue contains 
significantly lower levels of somatic instability. Furthermore, an experiment analysing 
data from 2 to 49-year-old FRDA patients and carriers has shown that mutation 
loads increase from 17% to 78.7%, respectively in an age dependent manner. Thus 
it can be concluded that somatic instability occurs mainly after early embryonic 
development and it develops progressively through the life (De Biase et al., 2007). 
Several models explain the mechanisms of repeat instability and all of them support 
a role for replication in repeat instability (Pearson et al., 2005). Forming secondary 
structure during replication can provide an explanation for repeat contraction and 
expansion. During replication of triplet repeat, the single-stranded part of lagging 
strand forms hairpin. Replication across hairpins results in contraction and slippage 
of nascent lagging strand leads to expansion (Figure 1.2) (Heidenfelder et al., 2003; 
Mirkin, 2006). Recently, it was demonstrated that expanded GAA repeats at the FXN 
locus in FRDA obstructed the progression of replication machinery and allowed the 
replication forks to proceed predominantly in a 3′-5′ direction, which could promoted 
Chapter 1: Introduction 
10 
 
repeat expansion (Gerhardt et al., 2016). In addition, recent studies have shown that 
changes in epigenetic status surrounding repeat expansions also contribute to 
repeat instability (Libby et al., 2008; Dion and Wilson, 2009). A comparative analysis 
of the epigenetic context of disease-associated trinucleotide repeats (TNRs) and 
random set of repeats revealed that the expansion-prone repeats differ from 
background TNRs in their epigenetic profiles. This data indicates that certain 
epigenetic status is associated with repeat expansion (Essebier et al., 2016). 
 
Figure 1.2: R epeat  instabilit y during replication.  
1.5 Abnormal structures 
1.5.1 Abnormal triplex structure  
The exact mechanism through which the GAA repeat expansion leads to FXN gene 
silencing is not fully understood yet. Several mechanisms have been proposed to 
explain how the triplet expansion inhibits frataxin expression. It has been suggested 
that GAA repeat expansion allows the formation of non-B-DNA structures, such as 
triplex-based sticky DNA, R-loops, and heterochromatin formation at pathogenic 
FXN alleles, which can lead to frataxin deficiency. Bidichandani et al. (1998) 
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demonstrated that GAA expansion is associated with an unusual DNA structure and 
transcription deficiency in a length-dependent manner (Bidichandani et al., 1998; 
Rajeswari, 2012). The GAA.TTC repeat is a homopurine (R) – homopyrimidine (Y) 
mirror repeat, which can adapt non-B-DNA conformation, including triplexes (H-
DNA), sticky DNA or hairpin structures. The GAA repeat can form either R·R·Y or 
Y·R·Y intramolecular triplexes by fold- back mechanism. In both motifs, the purine 
has the central position and forms normal Watson-Crick pairs with the 
complementary pyrimidine strand (Figure 1.3). Binding of the third strand, containing 
either purine (R·R·Y) or pyrimidine (Y·R·Y), is through ‘Hoogsteen’ or ‘reverse-
Hoogsteen type’ of hydrogen bonding (Sakamoto et al., 1999; Grabczyk and Usdin, 
2000c; Sakamoto et al., 2001c; Mirkin, 2006). 
 
Figure 1.3: U nusual DN A structu res formed  by triplet repeat s. 
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1.5.2 Sticky DNA 
Sticky DNA is one of the suggested unusual DNA conformations that is proposed for 
the GAA.TTC repeats. Sakamoto et al. (1999) reported that in a negatively 
supercoiled plasmid at natural pH, association of two long GAA.TTC repeats in the 
R·R·Y configurations leads to the formation of sticky DNA. They proposed a strand 
exchange model in which two R·R·Y triplexes exchange their Y strands to form an 
extremely stable hybrid triplex (Figure 1.3) (Sakamoto et al., 1999). It has been 
reported that sticky DNA structure directly binds to RNA polymerase, sequesters it 
and thus, strongly impairs in vitro transcription in both a cis and trans manner 
(Sakamoto et al., 2001c). Sakamoto et al. (2001) showed that introducing 
interruptions into GAA repeats abolishes the formation of sticky DNA and therefore 
reduces its negative effect on GAA transcription (Sakamoto et al., 2001a). 
1.5.3 R-loops 
Several studies have provided evidence that the unusual DNA structure within the 
GAA repeat impedes transcription of the FXN mRNA. It has been proposed that 
triplex formation may prevent binding of transacting factors (TF) to transcription-
control sequences and abolish transcriptional enhancement (Kohwi and Kohwi-
Shigematsu, 1991), or alternatively it may trap the RNA polymerase and cause a 
pause site (Sakamoto et al., 2001c). Grabczyk and Usdin proposed a model to 
explain the role of DNA triplex in impeding the GAA repeat transcription. Their model 
suggests that transient formation of DNA triplexes behind of an advancing RNA 
polymerase within a long GAA.TCC tract leads to R-loop (RNA.DNA hybrid) 
formation. R-loop formation negatively affects FXN transcription elongation and 
consequently results in reduced frataxin mRNA and protein levels (Figure 1.4) 
(Grabczyk and Usdin, 2000a; Grabczyk and Usdin, 2000c). It has been 
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demonstrated that RNA.DNA hybrid formation is a fundamental feature of GAA 
repeat transcription (Grabczyk et al., 2007). Groh et al. (2014) observed R-loop 
formation over the expanded GAA region. Its level was in correlation with the GAA 
expansion length and it was co-localised with the H3K9me2 chromatin marker (Groh 
et al., 2014). Several studies have demonstrated that elimination of RNA.DNA 
hybrids by RNase-H, which specifically disrupts RNA.DNA hybrids, significantly 
improves mRNA elongation (Huertas and Aguilera, 2003; Groh et al., 2014). 
Moreover, observing this hybrid formation even in the ‘pre-mutation’ size alleles, 
suggests that RNA.DNA hybrid formation contributes to GAA repeat instability 
(Grabczyk et al., 2007). 
 




Figure 1.4: An intramolecular  triplex impedes transcription and gives r ise to RN A.DN A hybrid.  
Figure 
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1.6 Epigenetic changes in FRDA 
The word “epigenetic” literally means “on top of or in addition to genetics”. Based on 
new scientific findings, epigenetics is defined as ‘‘the study of changes in gene 
function that are mitotically and/or meiotically heritable and that do not involve a 
change in the DNA sequence.’’ (Dupont et al., 2009; Kanherkar et al., 2014). Major 
epigenetic mechanisms, include DNA methylation, histone modification and ncRNA-
mediated gene silencing. Disruption of these epigenetic mechanisms can alter gene 
expression by chromatin remodeling. Accumulative evidence suggests that mutation 
and non-B-DNA structure could account for epigenetic changes and heterochromatin 
formation, thereby impeding gene transcription (Chen et al., 1995; Al-Mahdawi et al., 
2008). Several epigenetic changes and abnormal heterochromatinisation have been 
identified in the immediate vicinity of the expanded GAA repeats of the FXN gene 
(Sandi et al., 2014). The first evidence for epigenetic involvement in FRDA came 
from a study by Saveliev and colleagues. In eukaryotes, DNA wraps around the 
histone proteins to form a nucleoprotein complex called "chromatin". 
Heterochromatin is a highly condensed and transcriptionally inaccessible type of 
chromatin, which contains large blocks of repetitive DNA sequences. 
Heterochromatin is invasive and has a tendency to affect the expression of nearby 
genes (Yandim et al., 2013). Saveliev et al. showed that in transgenic mice, 
juxtapositioning of GAA expanded repeats with heterochromatin-sensitive human 
CD2 (hCD2) transgene alters expression by position effect variegation (PEV) 
(Saveliev et al., 2003). They showed that irrespective of the chromosomal location of 
the hCD2 transgene, inclusion of the GAA repeats can supress hCD2 expression. In 
addition, they also reported that the overexpression of a powerful modifier of PEV, 
heterochromatin protein (HP1), in CD2 GAA transgenic mouse lines significantly 
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decreases CD2 expression, whereas in the absence of GAA, HP1 overexpression 
did not affect hCD2 expression (Saveliev et al., 2003). PEV occurs when a gene that 
was previously located in a euchromatic region, is positioned proximal to 
heterochromatic region. The relocated gene exhibits varied expression because of 
the change in its position (Elgin and Reuter, 2013). PEV is a hallmark of 
heterochromatin mediated gene silencing. Recent studies strongly suggest that 
epigenetic changes including DNA methylation, histone modifications and repressive 
chromatin formation are involved in the FXN gene silencing in FRDA (Elgin and 
Grewal, 2003; Herman et al., 2006). 
1.6.1 DNA methylation 
DNA methylation is a silencing epigenetic mark that involves the addition of a methyl 
group to the C5 position of cytosine in the context of CpG dinucleotides. Gene 
silencing is the predominant consequence of DNA methylation. Therefore, aberrant 
DNA methylation is a feature of a number of important human diseases, such as 
cancer in which DNA methylation in the promoter region of key tumour suppressor 
genes promotes oncogenic progression (Pook, 2012). Recently, a large amount of 
evidence has emerged to show that DNA methylation has an important role in repeat 
expansion diseases. Disease-associated DNA methylation has also been identified 
in other trinucleotide repeat expansion diseases, such as myotonic dystrophy type 1 
(DM1) (López Castel et al., 2010), fragile X syndrome (FRAXA) and FRDA. The 
expansion of CGG repeats to over 200 triplets within the 5′UTR of the FMR1 gene 
leads to hypermethylation of the CpG sites along the FMR1 promoter region, 
transcriptional silencing and development of fragile X syndrome (Chandler et al., 
2003; Naumann et al., 2009). Pathological expansion of of a G4C2 repeat in C9orf72 
is the most common genetic cause of frontotemporal lobar degeneration (FTLD) and 
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amyotrophic lateral sclerosis (ALS). A recent study showed that the increase of 
C9orf72 repeat length correlates with earlier disease onset, increased methylation 
states of 5′ CpG islands and reduced promoter activity (Gijselinck et al., 2016). In 
FRDA patients, similar patterns have been reported. The FXN gene has three 
putative CpG islands (Figure 1.5) (http://cpgislands.usc.edu/) and several studies 
have investigated the role of DNA methylation in FRDA. Studying DNA methylation 
status at the FXN locus has revealed an overall increase in the methylation of CpG 
island upstream of GAA repeat in FRDA derived lymphoblastoid cells (Greene et al., 
2007). Al-Mahdawi and colleagues also reported an increase in DNA methylation 
upstream of GAA repeats (UP) in two lines of FRDA YAC transgenic mice (YG8 and 
YG22) and clinically important FRDA tissue such as heart, brain and cerebellum (Al-
Mahdawi et al., 2008). A similar pattern was demonstrated in two large scale studies 
confirming the previous observation about hypermethylation in the UP region of the 
FXN gene in FRDA individuals. These studies reported a positive correlation 
between triplet expansion size, disease severity and the level of upstream 
methylation (Evans‐Galea et al., 2012) and a strong negative correlation between 
methylation level and the age of disease onset (Castaldo et al., 2008; Sandi et al., 
2013b; Yandim et al., 2013). Lorcinz and colleagues demonstrated that intragenic 
DNA methylation may also reduce transcription elongation efficiency by inducing 
heterochromatin formation, suggesting that intronic DNA methylation at the upstream 
region of the GAA repeat is involved in FXN gene silencing (Lorincz et al., 2004).  




1.6.2 Histone modifications 
Eukaryotic DNA is tightly packed into nucleosomes and a nucleosome is composed 
of DNA coiled around an octamer, which is made up of two copies of each histone 
protein- H2A, H2B, H3, and H4. There are different types of histone modifications, 
which can affect gene expression by determining accessibility of the DNA for 
transcription. The simplest and most extensively studied classes of histone 
modifications are the acetylation and methylation of lysine (K) residues. Acetylation 
of lysine is a hallmark of transcriptionally active chromatin. This is probably due to 
the presence of acetyl groups (CH3CO-) which can weaken the binding between the 
histones and negatively-charged DNA backbone and allow the chromatin structure to 
Figure 1.5: The human Frat axin (FXN) gene and its regu lato ry components.  
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open up (Allfrey et al., 1964; Halleck and Gurley, 1981; Yandim et al., 2013). Histone 
acetylation also results in the recruitment of chromatin remodeling factors that lead 
to more permissive and transcriptionally competent chromatin structure. Such factors 
are recruited through their acetyl-lysine recognition domains, known as 
bromodomains (BRD) (Swygert and Peterson, 2014; Ferri et al., 2016). 
Hyperacetylation of histone H3 and H4 are known as active marks, whereas 
methylation of H3K9 and H3K27 are known to be a hallmark of heterochromatin 
formation and subsequent gene silencing (Karmodiya et al., 2012; Wang et al., 
2008). It is commonly recognized that H3K9 and H3K27 methylation are important in 
heterochromatin formation. It is well established that a conserved histone 
methyltransferase (HMTase), SUV39H1/2, selectively methylates lysine 9 of histone 
H3 (Rea et al., 2000) and subsequently generates a binding site for HP1 proteins, a 
family of heterochromatic adaptor molecules (Lachner et al., 2001). In turn, HP1 
recruits more HMTases and creates a positive feedback loop, resulting in 
heterochromatin formation (Figure 1.6). On the other hand, H3K27 methylation is 
catalysed by polycomb repressive complex 2 (PRC2). Previous studies suggested 
that both markers recruit distinct protein machineries. However, recent studies 
showed that these marks frequently colocalise in the genome and they cooperate in 
gene silencing maintenance (Boros et al., 2014; Saksouk et al., 2015; van 
Kruijsbergen et al., 2015). Hypoacetylation of histone H3 and H4, with increased 
levels of H3K9 di- and trimethylation in the upstream of GAA repeat, were first 
reported histone modifications within the FXN locus (Herman et al., 2006). 
Investigating FRDA patient brain, cerebellum and heart tissues and YAC transgenic 
mice revealed significant levels of H3 and H4 histone deacetylation and increased 
H3K9 di- and tri-methylation at the promoter, downstream and upstream of the GAA 
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repeats (Al-Mahdawi et al., 2008). Furthermore, repressive marks such as H3K9me3 
and H3K27me3 and HP1, were highly enriched in 5′UTR of the FXN gene (De Biase 
et al., 2009). Kim et al. (2011) reported significantly decreased levels of H3K4me3 at 
a region immediately upstream of the GAA repeats. Numerous studies suggest that 
H3K4me3 modification is often positively correlated with transcription initiation and 
more accessible chromatin structure for transcription factors. In addition, it has been 
shown that H3K4me3 facilitates recruitment of transcription post-initiation factors and 
enhances the efficiency of transcript elongation. This finding indicates a defect in 
FXN transcription elongation rather than a defective transcriptional initiation in FRDA 
(Sims et al., 2007; Kim et al., 2011). H3K36me3 and H3K79me2 are known as a 
hallmark of transcription elongation. Decreased methylation of H3K79 and H3K36 in 
FRDA cell lines supports the idea that frataxin deficiency is a result of defective FXN 
transcription elongation (Kim et al., 2011; Sandi et al., 2013b; Sandi et al., 2014). 
However recent studies have demonstrated that repressive chromatin extends from 
the GAA repeat towards the FXN promoter and encompasses the FXN-TSS and 
renders it transcriptionally non-permissive, and thereby causes a severe deficiency 
of transcriptional initiation (Chutake et al., 2014a). Indeed, the transcriptional 
deficiency upstream of the expanded GAA-TR significantly correlates with repeat 
length (Chutake et al., 2014c). Taken together, recent studies demonstrate that the 
expanded GAA repeats impair expression predominantly at the initiation stage of 
transcription, but also block RNAPII elongation. 




Figure 1.6: Spreading  of heterochromat in  via HP1 and  SU V39H
. 
1.6.3 CTCF 
CCCTC-binding factor (CTCF) is an 82-kDa evolutionarily conserved and 
ubiquitously expressed 11-zinc-finger DNA-binding protein. 100% evolutionary 
conservation of the entire CTCF 11-Zn-finger region indicates that these domains 
are involved in a highly conserved biological function (Filippova et al., 1996). CTCF 
is a multifunction protein, initially characterised as a transcriptional repressor of the 
chicken c-myc gene (Lobanenkov et al., 1990; Klenova et al., 1993; Kim et al., 
2015). Later, CTCF was found to also function as a chromatin insulator. Indeed, it is 
the only insulator protein known in vertebrates. Insulators are DNA-protein complex 
that protect genes from inappropriate signals emanating from their surrounding 
environments (West et al., 2002). Insulators can function as enhancer-blockers and 
block enhancer-promoter interactions or act as barriers against spread of 
heterochromatin into a neighbouring domain (Yang and Corces, 2011). There are 
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several recent studies proposing that insulators may mediate three-dimensional 
looping of genomic regions with the primary goal of organising the eukaryotic 
genome into epigenetically heritable states (Yang and Corces, 2011; Herold et al., 
2012). The insulator activity of CTCF was first identified at the 5′ end of the chicken 
ß-globin locus. Bell et al. (1999) showed that CTCF was able to interfere with 
enhancer-promoter communication in a directional manner and separate the locus 
from neighbouring heterochromatin (Bell et al., 1999). The insulator function of CTCF 
was also reported at the imprinted Igf2 (insulin-like growth factor 2)–H19 locus. It 
was shown that CTCF can bind to the unmethylated imprinting control region (ICR), 
and block the access of Igf2 to the distal enhancer (Figure 1.7) (Bartolomei et al., 
1991; Bell and Felsenfeld, 2000).  
 
Figure 1.7: The neighbouring Igf2 and H 19 genes are reciprocally imprinted .  
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Some studies have suggested that CTCF may act as a barrier at heterochromatin 
boundaries and protect genes against PEV. Genome-wide studies of the localisation 
of CTCF in three cell types revealed that CTCF-binding sites are significantly 
enriched at the boundaries between the repressive H3K27me3 and active H2AK5ac 
domains, indicating that CTCF may be involved in the chromatin barrier function 
(Cuddapah et al., 2009). A recent study by Weth et al. (2014) has demonstrated that 
upon CTCF depletion, H3K27me3 spreads into the nearby active domain and 
thereby causes gene repression. They also showed that CTCF removes H3K27me3, 
a hallmark of repressed domain, and actively converts repressed chromatin into 
active chromatin (Weth et al., 2014).  
CTCF plays a role in several TNR diseases. Results from genome-wide mapping 
studies and studying TNR diseases such as myotonic dystrophy (DM1), 
spinocerebellar ataxia type 2 (SCA2) and type 7 (SCA7), and Huntington’s disease 
(HD), show that CTCF binding sites are present at one or both sides of repeat 
expansion regions (Filippova et al., 2001; Libby et al., 2008). The role of CTCF in 
establishing the local chromatin structure at repeats was first shown at the DM1 
locus, where two CTCF binding sites flank DM1 CTG repeats and restrict repressive 
chromatin structure to repeat region. Loss of CTCF binding in congenital DM1 was 
associated with the spread of heterochromatin into nearby regions (Cho et al., 2005). 
In FRDA, a single CTCF binding site has been identified in the 5′ untranslated region 
(5′UTR) region of the FXN gene. De Biase et al. (2009) reported that the GAA repeat 
expansion in FRDA is associated with severe depletion of CTCF in the 5′UTR of the 
FXN gene. However, since other genes were not found to be affected, it appears that 
CTCF depletion is not a generalised defect in FRDA (De Biase et al., 2009). 
Studying FRDA cerebellum also demonstrated that CTCF occupancy decreased to 
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the value of only 20% compared to unaffected cerebellum controls (Al-Mahdawi et 
al., 2013). It has also been reported that CTCF depletion in FRDA is associated with 
higher levels of an antisense transcript and heterochromatin formation at the FXN 
locus (De Biase et al., 2009).  
1.6.4 The role of antisense transcription in FRDA 
Antisense transcription refers to the transcription from the opposite strand of a 
protein coding strand (sense strand) and the production of a single stranded RNA, 
known as an antisense transcript. This antisense transcript may have a partial or a 
complete overlap with the sense transcript. Antisense transcripts are widespread in 
eukaryotic genomes. It has been estimated that at least 20% of human genes have 
an antisense partner (Chen et al., 2004). Similar to sense transcription, antisense 
transcription is driven by a promoter that can be an independent unidirectional 
promoter or a divergent promoter (bidirectional promoter) (Pelechano and Steinmetz, 
2013). Various models have been suggested to explain how antisense transcripts 
are involved in regulation of gene expression. In many organisms, antisense 
transcripts have emerged as key regulators of gene expression in an epigenetic 
manner. A classic example is mammalian X chromosome inactivation, in which XIST 
silences one of the two X chromosomes in females. The action of XIST is negatively 
regulated in cis by its antisense transcript, TSIX. TSIX transcription induces histone 
modifications and alters chromatin conformation in the XIST promoter region. It has 
been shown that loss of TSIX transcription abolishes heterochromatin formation at 
the XIST promoter and is associated with reduced CpG methylation and aberrant 
histone modification in the 5′ region of Xist gene (Ohhata et al., 2008).  
Antisense RNA can also affect expression of its sense partner by DNA methylation 
and chromatin modifications at the promoter region. Yu et al. (2008) reported that in 
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leukaemia, expression of p15, a well-known tumour suppressor gene (TSG), is 
negatively-regulated in cis and in trans by its antisense transcript, p15AS. p15AS 
transcription leads to dicer-independent heterochromatin formation through an 
increase in H3K9 dimethylation and a decrease in dimethylation of H3K4 in cells (Yu 
et al., 2008). Antisense RNA transcribed at the p21 locus, another TSG, represses 
p21 gene expression. The p21 antisense RNA acts as an effector molecule, which 
directs epigenetic regulatory complexes and H3K27me3 enrichment to the sense 
promoter region (Morris et al., 2008; Faghihi and Wahlestedt, 2009). Important 
evidence of the relationship between antisense RNA and DNA methylation was 
provided by Tufarelli et al. (2003). They showed that heavily methylated CpG islands 
and the silencing of the haemoglobin α1 gene (HBA2) in patients with a class of α-
thalassemia are correlated with the transcription of an antisense transcript. An 
aberrant LUC7L transcript which is transcribed from the opposite strand to HBA2 
gene, extends into the CpG-island region of HBA2 gene and causes 
hypermethylation and silencing of the HBA2 gene (Tufarelli et al., 2003; Morris, 
2012; Pelechano and Steinmetz, 2013). Antisense transcripts with a potential 
pathogenic impact have been detected in several repeat associated diseases. At the 
Huntington’s disease (HD) locus, a natural antisense transcript has been detected 
that regulates the level of HTT expression (Chung et al., 2011). It has been proposed 
that an antisense transcript spanning the CGG repeat region of FMR1, might 
contribute to the pathogenesis of fragile X syndrome (FXS) and fragile X-associated 
tremor and ataxia syndrome (FXTAS) (Ladd et al., 2007). Recent studies show that 
the FMRA1 antisense transcript, ASFMR1, supports a non-canonical type of protein 
translation called repeat associated non-AUG (RAN) translation, which derives the 
production of toxic proteins from CGG repeats (Krans et al., 2016). In addition, 
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studies suggest that antisense transcription in spinocerebellar ataxia type 8 (SCA8) 
(Moseley et al., 2006), amyotrophic lateral sclerosis/frontotemporal dementia 
(ALS/FTD) (Zu et al., 2013) and DM1 (Cho et al., 2005) is a fundamental pathologic 
feature of these repeat-associated diseases. The expanded allele in congenital DM1 
is associated with an antisense transcript emanating from the adjacent SIX5 
regulatory region, the loss of CTCF binding and the propagation of heterochromatin 
to the surrounding regions (Cho et al., 2005; Gudde et al., 2017). 
Literature supporting the notion that antisense transcripts are involved in 
heterochromatin formation and the regulation of their partner mRNAs expression 
inspired De Biase et al. (2009) to investigate the presence of any antisense 
transcript in FRDA. They performed a strand-specific reverse transcription PCR with 
a primer located upstream of FXN transcription start site 3 (TSS3) and discovered an 
antisense transcript overlapping with the CTCF binding site (Figure 1.8). This novel 
antisense transcript named FAST1 (FXN Antisense Transcript – 1) was produced at 
significantly higher levels in FRDA fibroblasts. Sequencing and BLAST analysis of 
the FAST-1 transcript confirmed that it was originated from the FXN locus. Higher 
levels of FAST-1 were associated with the severe CTCF depletion and coincidentally 
heterochromatin formation in the 5′ untranslated sequence (5′UTR) of the FXN gene 
(De Biase et al., 2009). A comparison of CTCF occupancy at the 5′UTR of fibroblast 
cell lines was carried out between two normal individuals versus two FRDA patients, 
revealing a four-fold reduction in CTCF in the 5′UTR of the FRDA samples. In 
addition, they examined CTCF occupancy at 2 other loci on chromosome 9q in 
FRDA and normal cell lines and showed that FRDA cells do not have a generalized 
defect of CTCF binding. The +1 nucleosome of the FXN gene includes the CTCF 
binding site in the 5′UTR. It is followed by a long nucleosome free region, which is 
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composed of the three reported TSS of the FXN gene (Figure 1.8) (De Biase et al., 
2009). De Biase and colleagues observed that knocking down CTCF by siRNA in 
wild type fibroblasts resulted in high levels of FAST1 and reduced FXN transcription. 
Moreover, they detected significant H3K9me3, H3K27me3 and HP1 enrichment in 
FRDA fibroblasts, suggesting repressive heterochromatin formation involving the +1 
nucleosome and ensuing transcriptional silencing of the FXN gene (De Biase et al., 
2009). (Sandi et al., 2013a) 
 
In order to determine the exact size and location of FAST-1, characteristics of FAST-
1 were investigated in our lab and a full length FAST-1 transcript with a total length 
of 523bp in size, was identified. Mapping the 3′ and 5′ ends of FAST-1 transcript onto 
the genome precisely localised them to nucleotides -359 and 164 of the FXN gene, 
respectively. A poly (A) signal was also identified in the FAST-1 sequence at 
nucleotide positions of -283 to -288 (Sandi and Pook, 2015). A tag corresponding to 
FAST-1 was identified in a study of the human antisense transcriptome (position 
Figure 1.8: The FAST- 1, an antisense transcript overlapping with the CTC F bind ing sit e.  
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70840691 on the “-” strand of chromosome 9 in the HCT116 cell line), which maps 
close to the start of intron 1 of the FXN gene (He et al., 2008) and encompasses the 
promoter region (Figure 1.8). This potential putative FAST-1 comprises a 462 base 
pair open reading frame, which encodes a putative 154 amino acids. The open 
reading frame is intact in humans and chimpanzees but it does not contain a Kozak 
consensus sequence (De Biase et al., 2009). The part of FAST-1 that has been 
amplified and used in this work is shown as a solid line in (Figure 1.9). 
 
Figure 1.9: The 5′  end  of FXN gene showing  the reg ion corresponding to the full  length FA ST-1 transcript.  
1.7 Mouse models 
1.7.1 Knock-out and knock in mouse models  
Cossée and colleagues generated an Fxn knock-out mouse model by deleting the 
most conserved and functionally important sequence of the Fxn gene, exon 4. 
Homozygous frataxin deletion resulted in the complete loss of frataxin function and 
early embryonic lethality (Cossée et al., 2000). Early embryonic lethality indicates the 
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need of residual frataxin levels for survival until after birth. Puccio and colleagues 
then developed two viable lines of conditional knock-out mouse models, in which Fxn 
was deleted in specific tissues. They generated a muscle frataxin-deficient line and a 
neuron/cardiac muscle frataxin-deficient line, which together could mimic several 
pathophysiological and biochemical characteristics of FRDA (Puccio et al., 2001). 
Since GAA repeat expansion is the main cause of FRDA and none of the knock-out 
mouse models had GAA repeat expansions, Miranda et al., inserted or ‘knocked in’ 
(GAA) 230 within the first intron of the Fxn gene. To achieve further reduction in 
frataxin levels, the knock-in (KI) mice were crossed with knock-out (KO) mice and 
KIKO mice Fxn -/230GAA were generated. KIKO mice showed 25-30% frataxin 
expression, but these mice did not initially show defects in motor coordination, iron 
metabolism, response to iron binding or GAA repeat instability (Miranda et al., 2002). 
However, neurobehavioral deficits have recently been discovered in KIKO mice 
(McMackin et al., 2017). 
1.7.2 FRDA YAC transgenic mouse models 
To investigate whether human frataxin can stay functional in a mouse environment 
and rescue the embryonic lethal phenotype of homozygous Fxn knock-out mice, a 
human wild-type FRDA yeast artificial chromosome (YAC) transgenic mouse line 
was crossed twice with heterozygous Fxn exon 4 deletion knock-out mice. The result 
was a phenotypically normal mouse line with no endogenous mouse frataxin that 
only expressed YAC-derived human frataxin (Pook et al., 2001). To study the 
relation of GAA repeat expansion to FRDA, Al-Mahdawi and colleagues introduced 
GAA repeat expansions into human YACs and generated two lines of transgenic 
mice, YG8 and YG22. Both of these mouse lines, showed intergenerational and age-
related somatic instability of the GAA expansion (Al-Mahdawi et al., 2004) reduced 
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levels of frataxin mRNA and protein expression and decreased aconitase activity (Al-
Mahdawi et al., 2006). 
1.8 Therapies 
Currently, there is no effective cure for FRDA, however different therapeutic 
approaches have been investigated to either treat the symptoms or address the 
cause of the disease (Figure 1.10). Although the exact molecular mechanisms 
underlying FRDA are not fully understood, unusual DNA structures and repressive 
chromatin formation as a result of GAA repeat expansion were proposed to play a 
role. It has been reported that the presence of complementary 
oligodeoxyribonucleotides (ODN) during transcription inhibits particular types of 
triplex formation in vitro and consequently this increases the yield of the full-length 
RNA. However, due to the high concentration required and the potential degradation, 
using unmodified ODNs in vivo is not practical (Grabczyk and Usdin, 2000a). Other 
molecules such as polyamides can disrupt formation of FRDA triplexes and sticky 
DNA by locking GAA repeat into double-stranded B-DNA structure and subsequently 
increase frataxin mRNA and protein levels in FRDA lymphoblast cells. However, 
microarray analysis of polyamide effects on the global gene expression has revealed 
that the polyamides significantly changed the expression of a small number of genes 
(Burnett et al., 2006). In a recent study, Corey and colleagues developed two distinct 
synthetic agents, an anti-GAA duplex RNA and a single-stranded locked nucleic acid 
LAN. These two synthetic nucleic acids employ same strategy to restore curative 
FXN levels in FRDA cells. They target GAA repeats and thereby, prevent R-loops 
and resultant repressive chromatin formation in FRDA cells. This study 
demonstrated that a simple binding to the mutant transcript is sufficient to re-activate 
frataxin expression in FRDA cells. No changes in GAA repeat-containing genes were 
Chapter 1: Introduction 
31 
 
reported in this study (Li et al., 2016). Another novel therapeutic strategy is delivering 
a functional FXN gene to the main site of pathology. It has been reported that 
delivering functional FXN into heart cells of a mouse model with complete deletion of 
frataxin in cardiac and skeletal muscle, can completely prevent the development of 
cardiac disease and even reverse it when cardiomyopathy is already established 
(Perdomini et al., 2014).  
FRDA is caused by a partial deficiency of FXN protein. Therefore, by delivering a 
functional protein into the main site of pathology exogenously, the FRDA phenotype 
can be rescued. Payne and colleagues used a cell-penetrant peptide, TAT, to deliver 
human FXN to mitochondria in FRDA fibroblast cells and conditional knock-out mice. 
They reported reduced sensitivity to oxidant stress in FRDA fibroblast cells and 
increased cardiac function, aconitase activity, growth velocity and lifespan in 
conditional Fxn knock-out mice after treatment with TAT-FXN fusion protein (Vyas et 
al., 2012). Since GAA repeat expansions induce epigenetic changes and 
heterochromatin formation, resulting in transcriptional silencing of the FXN gene, the 
potential reversibility of epigenetic changes has made them attractive targets for 
FRDA treatment. In particular, histone deacetylase inhibitors (HDACi) have been 
used to boost frataxin expression. It has been reported that treating KIKI mice with a 
pimelic o-aminobenzamide HDACi (compound 106) restores normal frataxin levels 
and increases acetylation at lysine residues in histones H3 and H4 near the GAA 
repeat (Rai et al., 2008). Also, long term application of HDACi compound 109 in 
YG8R FRDA mice produced increased frataxin protein in brain and improved motor 
coordination and locomotor activity (Chutake et al., 2016; Sandi et al., 2011). A 
phase Ib clinical trial with HDACi compound 109/RG2833 has been successfully 
completed (Soragni et al., 2014; Bürk, 2017). Nicotinamide (vitamin B3) is another 
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HDACi that has been reported to upregulate FXN expression in different FRDA 
models (Chan et al., 2013). A clinical study revealed that nicotinamide can 
significantly upregulate frataxin protein and attenuate heterochromatin formation in 
FRDA patients, however, no significant clinical improvement was reported (Libri et 
al., 2014). Furthermore, compound 5 (C5) is a small molecule with HDACi activity, 
which has been shown to restore FRDA histone acetylation to wild type levels and 
increase the FXN expression in FRDA patient-derived primary lymphocytes. The C5 
molecule was identified by using an FRDA genomic DNA reporter cell model to 
screen and pre-select potential therapeutic compounds. Using this type of cell model 
system can considerably increase the efficiency and speed of primary compound 
screening (Lufino et al., 2013). To justify further development of such candidate 
therapeutic compounds, FRDA mouse models can be used to validate the initial 
results obtained from in vitro studies (Al-Mahdawi et al., 2008). 




Figure 1.10: Patho logical mechan isms and therapeutic strat egies in  FRD A. 
1.9 Aims of study 
The exact molecular mechanisms causing FRDA are not yet well understood. 
However, accumulating evidence suggests that epigenetic alterations are involved in 
FXN gene silencing. In this research project, I aimed to study any possible effects 
that FAST-1 might have on the FXN gene expression. Initially, I established stable 
HEK293, HeLa and fibroblast cell lines that overexpress FAST-1. Then, we 
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examined the FXN mRNA and protein expression, DNA methylation and histone 
modification profiles of the FAST-1 overexpressing cells, as described in Chapter 3.  
To investigate whether knocking down FAST-1 could improve FXN expression in 
FRDA cells, as the next step of our study, I used the shRNA system to knock down 
FAST-1 in FRDA cells, as described in Chapter 4. 
 Recently, the Ataxia Research Group at Brunel University London established a 
new YG8-derived FRDA mouse model, YG8LR, which was shown to have an 
average of 420 GAA repeats. YG8LR mice show decreased levels of FXN mRNA 
and frataxin protein in various tissues compared to YG8sR and control mice (Saba 
Saqlain, PhD thesis). To further characterise our new mouse model, I analysed the 
expression levels of FAST-1 and histone modifications in YG8LR mice, as described 
in Chapter 5. 
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2.1 General cell culture maintenance 
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) high glucose, 
GlutaMAX™ supplement (Gibco) with addition of 10% foetal bovine serum (Gibco) 
and 2% penicillin/streptomycin 5000U/ml (Gibco). The complete media was filtered 
through a 0.22m pore size filter unit (Nalgene). The prepared medium was stored at 
4°C. Cells were grown at 37°C in 5% CO2 humid incubator. 
2.1.1 Thawing of cryopreserved cells 
Vials were taken out from liquid nitrogen and transported in dry ice. To release any 
residual liquid nitrogen, a soaked tissue in 70% alcohol was wrapped around the 
vials and lids were loosened. To rapidly thaw the cells, the vials were put in a 37°C 
water bath for 1-2 minutes. Cells were transferred into a 15ml conical tube containing 
10ml pre-warmed complete culture medium and centrifuged for 5 minutes at 200xg. 
The supernatant was discarded and the pellet was resuspended in 5ml medium and 
transferred into either 25cm2 or 75cm2 flasks containing complete culture medium. 
Cells were incubated at 37°C, 5% CO2 with 92-95% humidity.  
2.1.2 Cell freezing medium 
Freezing medium was comprised of 10% (v/v) DMSO and 90% DMEM culture 
medium containing penicillin/streptomycin and FBS.  
2.1.3 Passage of cultured cells 
When cells reached 80-90% confluency they were passaged into fresh growth 
medium. First, DMEM, trypsin and PBS were warmed in a 37°C water bath. After 
washing cells with PBS, approximately 1ml of 0.25% Trypsin/EDTA was added and 
the flask was incubated in a humidified 5% CO2 incubator at 37°C for 5 minutes to 
allow cells to detach from the flask. Trypsin/EDTA was inactivated by adding 5ml of 
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DMEM. Cells were pelleted at 200xg for 5 minutes. The supernatant was aspirated 
off and cells were recovered in DMEM and were subcultured at a 1:2 or 1:4 split 
ratio. 
2.1.4 Mycoplasma PCR test 
Mycoplasma PCR was carried out using MycoSensor PCR Assay Kit (Agilent 
technologies). 100l of cell culture supernatant was heated at 95° for 5 minutes and 
centrifuged for 1 minute. StrataClean resin was resuspended by vortexing for 30 
seconds and 10l of it was added to heated supernatant and mixed by flicking the 
tube. To pellet the resin, the mixture was centrifuged for 1 minute at 13K rpm 
(microfuge) and 20l of supernatant was transferred to a PCR tube on ice. The 
supernatant was used as the PCR template. A premaster mixture was prepared for 4 
reactions by adding the following solutions:  
- 54l of PCR grade water 
- 100l of REDtaq  
-  8l of primer mix  
- 16l of internal control template 
45l of mastermix was transferred into each PCR tube and 5l of test samples 
(HEK293 and HeLa) were added to the corresponding tubes. 5l of sterile water and 
5l of positive control template were added to negative control and positive control 
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Table 2.1: Mycoplasma test PCR program 
Step Temperature Time Cycles 
Initial denaturation 94°C 30sec 1 











Extension 72°C 10mins 1 
 
To visualize the results, 10l of PCR product was run on a 1% agarose TBE mini-gel 
along with a 1kb plus DNA size marker (Invitrogen) at 75V for ~30 minutes (Figure 
2.1). The following table 2.2 was used to interpret the results. 
Table 2.2: Mycoplasma test PCR results 
 
 
PCR template PCR product(s) Result 
Cell culture extract + 
internal control template 




Heavy Mycoplasma infection 
No Mycoplasma infection 
Positive control + 
internal control template 
 
None or 315bp only 
315bp and 500bp 
Failed PCR reaction 
Expected control result 
 
Negative control + 
internal control template 
500bp 
315bp and 500bp 
Expected control result 
Contaminated reagents 




Figure 2.1: M ycoplasma PCR  reaction products on  a standard  1% agarose gel.  
2.2 Assay standards and kit 
REDTaq® ReadyMix™ PCR Reaction Mix MERCK 
 
Taq DNA Polymerase PCR Master Mix QIAGEN 
 
Fast SYBR™ Green Master Mix Applied Biosystems 
 
Power SYBR® Green Master Mix Applied Biosystems 
 
Plasmid miniprep/ maxiprep/ megaprep kit QIAGEN 
 
Cloned AMV First-Strand cDNA Synthesis Kit MERCK 
 
DNaseI treatment RNase free kit Thermo ScientificTM 
 
Custom Plus TaqMan Copy Number Assays Thermo ScientificTM 
 
BCA Protein Assay Kit Thermo ScientificTM 
 
GENECLEAN® III Kit MP Biomedicals  
 
Neon™ transfection system Thermo ScientificTM 
 
Dipstick Assay Kit for Frataxin Quantity 
 
ABCAM 
Chromatrap ChIP QPCR Kit 
 
Chromatrap  
Custom Lentiviral shRNA MERCK 
 
Aconitase Assay Kit Cambridge Biosciences Ltd 




Primer sequences were obtained either from previous studies (as indicated) or newly 
designed and all primers were purchased from Sigma-Aldrich. 
Table 2.3: Primers used for genotyping 
Primer name Sequence (5'-3') Amplicon size 
GAA repeat (Campuzano et al. 1996)  
GAA – F 









FXN knock-out (Cossee et al. 2000)  
WJ5  
WN39 (WT specific)  










Table 2.4: Primers used for quantification of FXN expression 
Primer name Sequence (5'-3') Amplicon size 
FXN expression (Human Specific) (Al-Mahdawi et al., 2008) 
Fxn-h-RT-F                                                           CAGAGGAAACGCTGGACTCT 














HPRT (Human) (Bayot et al., 2013) 
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Table 2.5: Primers for amplifying FAST-1 transcript 
 
Table 2.6: Primers used for ChIP qPCR analysis 
Primer name Sequence (5'-3') Amplicon size 
FXN – 5′UTR (De Biase et al., 2009) 
FXN-ChIP-R                                                        CGAGAGTCCACATGCTGCTCC                      
FXN-ChIP-F                                                        TCCTGAGGTCTAACCTCTAGCTGC  




FXN – promoter(Herman et al., 2006) 
FXN-pro - F                                                        CCCCACATACCCAACTGCTG 
FXN-pro - R                                                        GCCCGCCGCTTCTAAAATTC 
 
147bp 
H19 – CTCF positive(Burke et al., 2005) 
h-H19 - F                                                             CCCATCTTGCTGACCTCAC  





H19neg – CTCF negative (Burke et al., 2005) 
h-H19neg - F                                                      CATCATGGTGTCCTCACAGG  










Primer name Sequence (5'-3') Amplicon size 
FAST-1 cDNA synthesis  (De Biase et al., 2009) 
FAST RT                                                    CCAAGCAGCCTCAATTTGTG 
 
 
PCR for FAST-1 cDNA (De Biase et al., 2009) 
FAST F1                                                                 GTGGGGGAGCAGCTAGAGG 






N- FAST F2  
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2.4 General techniques 
2.4.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA fragments on the basis of 
their size. 0.8%-2% agarose gels were prepared in 1×TBE. The agarose was 
completely dissolved in TBE by using a standard microwave and allowed to cool for 
5 minutes. Ethidium bromide was added to a final concentration of 0.2μg/ml. The gel 
was poured in a gel tank and allowed to set. 6×Orange G loading dye was added to 
samples to get a final concentration of 1x electrophoresis buffer (1xTBE) was added 
on top of the gel. Samples along with 1kb plus ladder (Figure 2.2) were run at 50V 
until to get a good band separation. Gels were visualized and documented by using 
a UVP GDAS (Gel Documentation Analysis System) 1200 under the ultraviolet light. 
Figure 2.2: 1kb p lus DN A ladder.  
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2.4.2 DNA extraction by the phenol/chloroform method 
This method was used to extract genomic DNA from samples where greater DNA 
quality was necessary. Tissue samples or cell pellets were collected in Eppendorf 
tubes and 400μl of digestion buffer (100mM Tris (pH8.0), 5mM EDTA, 200mM NaCl, 
0.2% (w/v) SDS) and 10μl of proteinase K (50mg/ml) were added, followed by a brief 
vortex and incubation at 55°C overnight. After digestion, by adding required sterile 
water the initial volume was adjusted to 200l. An equal ratio of phenol was added to 
the mixture (200l) and it was vortexed for 30 seconds. The tube was centrifuged at 
14k rpm (microfuge) for 5 minutes at 4°C. The upper aqueous phase was removed 
and transferred to a fresh Eppendorf tube and 1 volume of chloroform/isoamyl 
alcohol (24:1, v/v) was added. The samples were mixed by vortexing for 30 seconds 
and centrifuged at 14k rpm for 10 minutes at 4°C. The upper layer was transferred to 
a fresh Eppendorf tube. 1/10 volume of 3M sodium acetate (pH 5.2) and 2 volumes 
of absolute ethanol were added. The mixture was incubated at -80°C overnight. To 
precipitate DNA, the tube was centrifuged 14k rpm for 30 minutes at 4°C and the 
DNA pellet was washed with 70% ethanol. After centrifuging for 8 minutes, the 
ethanol was drained off carefully and the DNA pellet was air-dried for 5 minutes. The 
DNA pellet was resuspended in 50l of TE buffer. 
2.4.3 Extraction of total RNA using the Trizol® method (Invitrogen)  
Total RNA was extracted from approximately 10
6 
cells. Medium was first aspirated 
off and cells were rinsed with 10ml of ice cold PBS. Trizol® was added directly to the 
cells and it was incubated for 5 minutes at room temperature. Cell lysate was passed 
through a pipet up and down several times. For the extraction of RNA from tissues, 
initially 30mg of a tissue was homogenized in 1ml of Trizol® in an Eppendorf tube. 
Samples were mixed and incubated for 10 minutes at room temperature. 0.2ml of 
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chloroform per 1ml of Trizol® was added, followed by vigorous shaking of samples 
for 15 seconds and incubation for a further 15 minutes at room temperature. 
Samples were phase separated by centrifugation at 14K rpm (microfuge) for 15 
minutes at 4°C. The upper aqueous phase (~0.5ml) was then transferred to a 
freshly-labelled Eppendorf tube and RNA was precipitated by adding 0.5ml of 
isopropyl alcohol. Samples were incubated for 10 minutes at room temperature and 
centrifuged at 14K rpm for 15 minutes at 4°C. The supernatant was carefully 
removed and the RNA pellet was washed once with 1ml of 75% ethanol (made with 
DEPC-water) and centrifuged again at 8K rpm for 5 minutes at 4°C. The supernatant 
was removed carefully and the RNA pellet was briefly dried for 5-10 minutes and 
resuspended in 20μl of DEPC-water. RNA samples were stored at -80°C.  
2.4.4 Checking RNA integrity 
Isolation of intact RNA is essential for quantitative gene expression analysis. To 
check RNA integrity an aliquot of the RNA samples along with a DNA ladder were 
run on a 1.5% agarose gel. Intact total RNA had sharp, clear 28S and 18S rRNA 
bands (eukaryotic samples) (Figure 2.3). 
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Figure 2.3: Intact RN A. 
 
2.4.4 DNase I treatment of RNA 
Deoxyribonuclease I, Amplification Grade (DNase I, Amp Grade, ThermoScientific) 
was used to eliminate DNA contamination from RNA samples. To remove any 
genomic DNA following reagents were added to 1μg of total RNA:  
- 1μl 10×DNase I reaction buffer  
- 2μl DNase I, Amp Grade, (1U/μl)  
- DPEC-treated water to 10μl  
The reaction was incubated for 15 minutes at room temperature. DNaseI reaction 
was inactivated by adding 1μl of 25mM EDTA solution to the reaction mixture and 
heating it for 10 minutes at 65°C. The RNA samples were used immediately for 
reverse transcription or stored at -80°C. 
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2.4.5 Complementary DNA (cDNA) synthesis 
Complementary DNA (cDNA) was synthesized by using cloned AMV first-strand 
cDNA synthesis kit (Invitrogen). On ice, 5μl (1μg) of RNA was added to 7μl of primer 
component mastermix. 
For Oligo(dT) cDNA synthesis, 5μl (1μg) of RNA was added to 4μl of DEPC-water, 
2μl 10mM dNTP mix and 1μl Oligo(dT)20 primer. For FAST RT strand specific cDNA 
synthesis, 5μl (1μg) of RNA was added to 4.5μl DEPC-water, 2μl 10mM dNTP mix 
and 0.5μl FAST RT (10μM) primer. All the preparation steps were carried out on ice. 
The mixtures were heated at 65°C for 5 minutes and then placed on ice immediately 
after. To bring all the contents of the tubes to the bottom, samples were centrifuged 
briefly and the following reagents were added in order: 4μl 5xcDNA synthesis buffer, 
1μl DEPC-water, 1μl 0.1M DTT, 1μl RNase OUT™ (40U/μl) and 1μl cloned AMV RT 
(15U/μl). The 20μl reaction mixture was gently mixed by flicking and briefly 
centrifuged. The reaction mixture was incubated at 55°C for 60 minutes. The 
reaction was terminated by heating the samples at 85°C for 5 minutes. The cDNA 
samples were used immediately or stored at -20°C (Sandi and Pook, 2015). 
2.4.6 Determination of RNA/DNA concentration and purity  
RNA/DNA concentration and purity was determined by using NanoDrop™ 2000c 
spectrophotometer (NanoDrop, Thermo Scientific). The absorption (A) of ultra violet 
light (UV-light) was measured at 260nm to determine the DNA/RNA concentration 
and the quality was determined by using A260/280 ratio. 
2.4.7 Polymerase chain reaction (PCR) - standard or gradient PCR  
Polymerase chain reactions (PCR) were performed using a Bio-Rad tetrad PCR 
machine. The right concentrations and precise annealing temperatures of each of 
the primer set were assessed by gradient PCR. In the gradient PCR, the annealing 
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temperature was set to a range of ±5°C to the annealing temperature calculated by 
the following formula:  
TM = 4(G+C) + 2(A+T) °C  
TA = TM - 5°C (where TM-melting temperature, TA-annealing temperature) 
2.4.8 GAA PCR 
1μl of extracted DNA was used as a template for GAA PCR together with 24μl of the 
reaction mixture. The GAA PCR primers (Table 2.7), master mix components (Table 
2.8) and conditions are shown in (Table 2.9). 
Table 2.7: GAA PCR primers 
Primer name Sequence (5'-3') Amplicon size 
GAA Forward GGGATTGGTTGCCAGTGCTTAAAAGTTAG  
421bp GAA Reverse GATCTAAGGACCATCATGGCCACACTTGCC 
 
Table 2.8: GAA PCR master mix components 
Component Volume(μl)/Reaction 
2×Qiagen Master Mix (Qiagen) containing MgCl2, Taq DNA polymerase and 
dNTPs) 
12.5μl 
Q buffer 5µl 
50µM GAA reverse primer 1µl 
50µM GAA forward primer 1µl 
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Table 2.9: GAA PCR program 
Step 
 
Temperature Time Cycles 
Initial denaturation 
 


























68°C 10mins 1 
 
To visualise the PCR products, a 1% agarose gel with 50ml 1×TBE (89mM Tris-
borate, 2mM EDTA, pH 8.3) buffer was prepared (section 2.4.1).10µl of samples 
along with 1kb+ DNA ladder (Invitrogen) were run at 75V for 30-60 minutes. Three 
controls were used. Control samples with known genotype were used as positive 
and negative controls. A blank control containing no DNA was used as a 
contamination control. No PCR amplification was expected in negative and blank 
controls (Figure 2.4). 
 
Figure 2.4: Agarose gel electrophoresis of GAA PCR  reaction  products f rom FRD A transgenic mouse t issues 
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2.4.9 Fxn KO PCR 
To determine the knockout genotype of Fxn (wild-type, heterozygous, rescue) the 
KO PCR was performed (Figure 2.5). 1μl of extracted DNA was used as a template 
for PCR together with 24μl of the reaction mixture. The KO PCR primers (Table 
2.10), master mix components (Table 2.11) and conditions are specified in (Table 
2.12). 
 
Figure 2.5: Agarose gel electrophoresis of Fxn K O PCR reaction  products from FRD A transgenic mouse tissues.  
 
Table 2.10: Fxn KO PCR primers 
Primer name Sequence (5'-3') Amplicon size  
WJ5 CTGTTTACCATGGCTGAGATCTC Wild-type allele (WJ5-WN39) = 520bp 
WN39(WT specific) CCAAGGATATAACAGACACCATT  
WC76 (KO specific) CGCCTCCCCTACCCGGTAGAATTC Mutant allele (WJ5-WC76) = 245bp 
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Table 2.11: Fxn KO PCR master mix components 
Component Volume(μl)/Reaction 
REDTaq sigma master mix containing MgCl2, Taq DNA polymerase and 
dNTPs) 
12.5μl 
50µM WJ5 0.5µl 
50µM WN39 0.5µl 
50µM WC76  0.5µl 
dH2O to 25µl 
 
Table 2.12: Fxn KO PCR program 
Step 
 
Temperature Time Cycles 
Initial denaturation 
 














72°C 10mins 1 
 
2.4.10 Quantitative real-time PCR (qPCR)  
Quantitative real-time PCR (qPCR) amplification was performed using SYBR Green 
(Applied Biosystems) in a QuantStudio 7 Flex Real-Time PCR instrument (Applied 
Biosystems). Reactions were carried out in 96 well plates (MicroAmp, Applied 
Biosystems), in triplicates, and in a final volume of 10μl containing optimized 
concentration of forward and reverse primers and gDNA/cDNA. Distilled water was 
added to non-template control reactions instead of template DNA. Mastermix was 
prepared on ice while trying to minimize light exposure. The reaction plate was 
sealed with MicroAmp® Optical Adhesive Film (Applied Biosystems) and centrifuged 
briefly at 1k rpm. The cycling conditions were selected according to the master mix 
Chapter 2: Material and methods 
51 
 
used and application. Alongside each real-time PCR run, a dissociation curve was 
performed by gradually increasing the temperature from 60°C to 95°C. Relative 
quantification values were determined by the 2-ΔΔCt method. 
2.4.11 Protein extraction 
107 cells were collected in a 1.5ml Eppendorf tube and homogenised in 300 of RIPA 
(RadioImmunoPrecipitation Assay) buffer (Sigma-Aldrich) and 12μl of 25xprotease 
inhibitor (ThermoScientific). Samples were centrifuged at 14k rpm for 30 minutes at 
4°C and the clear supernatant was collected in a fresh Eppendorf tube. A 50μl 
aliquot of the protein lysate was taken for BCA assay and DTT was added to the rest 
at a final concentration of 1mM. The protein lysates were stored at -80°C.  
2.4.12 Determination of protein concentration using the BCA protein assay 
The protein concentration was measured using a Pierce® BCA Protein Assay Kit 
(Thermo Scientific) following the manufacturer's instructions. This method combines 
the reduction of Cu2+ to Cu1+ by protein in an alkaline medium with highly sensitive 
and selective colorimetric detection of the cuprous cation (Cu1+) using bicinchoninic 
acid (BCA). The purple-coloured product of this assay has a strong absorbance at 
562nm. To construct a standard curve, the contents of one bovine serum albumin 
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Table 2.13: Preparation of BSA standards for BCA analysis 
Tube BSA volume dH2O volume Final volume Final concentration 
A 30 μl 10 20 1500μg/ml 
B 20 μl 20 20 1000μg/ml 
C 20 μl of A 20 40 750μg/ml 
D 20 μl of B 20 20 500μg/ml 
E 20 μl of D 20 20 250μg/ml 
F 20 μl of E 20 30 125μg/ml 
G 10 μl of F 40 50 25μg/ml 
H 0 40 40 0 
 
To perform BCA assay, protein lysate was diluted 1:10 with dH2O.To prepare 
working buffer, 50 parts of BCA Reagent A were mixed with 1 part of BCA Reagent 
B (50:1, Reagent A: B). 10 μl of BSA standards and diluted protein samples were 
added to 200 μl of working buffer (A+B). The BCA reactions were incubated for 30 
minutes at 37°C.  
To measure A562, the Protein BCA application was selected from NanoDrop™ 2000c 
home page. A standard curve was prepared by plotting A562 measurement for each 
BSA standard against its concentration. The standard curve was then used to 
determine the protein concentration of each study sample. 
2.4.13 Dipstick assay 
The level of frataxin protein was measured by lateral flow immunoassay with the 
Frataxin Protein Quantity Dipstick Assay Kit (MitoSciences) according to the 
manufacturer’s instructions. 
First 2μg of protein in 25μl of extraction buffer (buffer A) was mixed with 25μl of 
2xblocking buffer (buffer B) and was added to individual wells on a 96-well plate 
(provided with the kit) with gold-conjugated monoclonal antibody at the bottom of 
each well. The samples were incubated for 5 minutes, allowing the gold-conjugate to 
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hydrate. The mixture was then resuspended gently using a pipette and dipsticks 
were inserted into the well. The samples were allowed to wick up onto the dipstick 
until the entire sample volume was absorbed (15-20 minutes). The dipsticks were 
washed for 20 minutes with 30μl of washing buffer (buffer C) in an empty well of the 
microplate. The dipstick was air-dried for approximately 20 minutes and the signal 
intensity was measured with a MS-1000 Immunochromatographic Reader 
(MitoSciences) (Figure 2.6). 
Figure 2.6: Quantification  of human  FXN  using d ipstick immunoassay.  
 
2.4.14 Chromatin immunoprecipitation (ChIP) analysis 
This procedure was performed by using ChIP qPCR kit (Chromatrap) with an 
acetylated H3 (Lys9) (Upstate, 7-352), trimethyl-H3 (Lys9) (Upstate, 07-442) and 
CTCF (Upstate, 7-729), antibody on formaldehyde cross-linked samples. Initially, 4 
million HeLa cells were cultured in a T75 flask. Once the flask became confluent, 
cells were washed with warm PBS and fixed in basic cell culture media containing 
1% formaldehyde for 10 minutes at room temperature on a rocking platform. To 
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quench the reaction, the fixation solution was removed and 4ml of 0.65M glycine was 
added and cells were incubated for 5 minutes at room temperature with gentle 
agitation on a rocking platform. The cells were collected by scraping in ice cold PBS 
containing 1l of proteinase inhibitor cocktail and pelleted by centrifugation at 
3500×g for 5 minutes at 4°C. The cell pellets were resuspended in 800l Hypotonic 
Buffer (provided by the kit) and incubated at 4°C for 10 minutes. The hypotonic 
slurries were pelleted by centrifugation at 5000xg for 5 minutes at 4°C and they were 
resuspended in 500l of pre-warmed to 40°C Lysis buffer (provided by the kit). 
Samples were then incubated at 4°C for 10 minutes. Bioruptor® Pico sonication 
System (Diagenode) was used to achieve the desired length of DNA fragments 
(100bp-500bp). Chromatin samples from HeLa cells were sheared for 5 cycles of 30″ 
on/ 30″ off, using 0.1ml Bioruptor® Microtubes. The cell debris was removed by 
centrifugation for 10 minutes at 14K rpm (microfuge) 4°C, and the DNA collected as 
the supernatant phase. 1l of proteinase inhibitor cocktail was added to the samples. 
To assess the quality of the DNA shearing, a 25μl aliquot of sonicated and 
unsonicated chromatin were reverse-cross-linked by adding 5μl of 1M NaHCO3 and 
5μl of 5M NaCl in a final volume of 50μl. Samples were then incubated at 65°C for 2 
hours. 1μl of Proteinase K (provided with the kit) was added and incubated for 1 hour 
at 37°C. The reaction was stopped by adding 2μl of Proteinase K stop solution 
(provided with the kit). 5μl of the reverse-cross-linked chromatin samples were 
separated on a 1% agarose 1xTBE mini-gel. To have a correct size assessment, all 
chromatin samples were reverse-cross-linked before agarose gel electrophoresis 
(Figure 2.7). DNA fractionation was considered acceptable when the majority of the 
DNA was ≤500bp. The chromatin concentration was measured at 260nm. The 
reading was multiplied by 2 to account for the dilution during the reverse cross-
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linking. The chromatin concentration was used to determine the volume of chromatin 
needed for the immunoprecipitation (IP) step. 
 
 
To minimise non-specific background interference from suspended solids, the 
sonicated chromatin was spun down at 16000×g for 10 minutes at 4°C.  
A molar ratio 1:2 of chromatin to antibody was used for each IP. 2g of sheared 
chromatin, 4g of antibodies of interest, 5μl of Wash Buffer 1 (provided with the kit) 
and 1μl of PIC were added to a final volume of 40μl. For every antibody IP, the 
equivalent amount of chromatin in a final volume of 20μl was set aside and labelled 
as input. Spin Columns were prepared by adding 600μl of the Column Conditioning 
Buffer (provided with the kit). The conditioning step was repeated twice. Once the 
columns were ready, IP slurries were transferred to corresponding Chromatrap® 
spin column and incubated for 1 hour at 4°C on a rocking platform with gentle 
agitation. Each column was washed with the provided wash buffers five times. The 
chromatin was subsequently eluted by adding 50μl of elution buffer to each column, 
followed by incubation at RT, for 15minutes. The samples were centrifuged for 30 
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seconds at top speed. The cross-links were reversed and DNA was used for 
downstream processing, PCR and qPCR. 
Real-time PCR was performed in triplicate using a QuantStudio 7 Flex Real-Time 
PCR instrument (Applied Biosystems). Each qPCR reaction was carried out in 
triplicates in a 10µl reaction volume by using 2µl of the eluted immunoprecipitated 
DNA, 5µl of Fast SYBR Green Master Mix (Applied Biosystems) and 12.5pmol of 
each of the respective forward and reverses primers (Table 2.6). Relative 
quantification values were normalised to input and minus antibody samples, and 
finally determined in relation to a control region. 
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In order to determine if FAST-1 has any effect on FXN gene expression, FAST-1 
was overexpressed in 3 different non-FRDA cell lines, HeLa, HEK293 and fibroblast, 
each with normal FXN expression. Previously, full-length FAST-1 was isolated and 
characterised in our lab. To allow overexpression of FAST-1, the full-length FAST-1 
transcript was first cloned into a mammalian expression vector with a strong 
cytomegalovirus (CMV) promoter to drive high levels of FAST-1 transcription. The 
three non-FRDA human cell lines were stably transfected with the recombinant 
plasmid and increased expression of the FAST-1 was confirmed by isolating total 
RNA and measuring FAST-1 expression levels in the transfected cell lines by 
quantitative real-time reverse transcription PCR (qRT-PCR). After confirming FAST-1 
overexpression, FXN mRNA expression changes were studied in the FAST-1 
overexpressing cell lines by qRT-PCR. In addition, frataxin protein expression levels 
were also measured using the frataxin lateral flow dipstick immunoassay.  
FAST-1 expression levels in stably transfected cell lines were not only affected by 
the promoter driving FAST-1 expression, but also by the FAST-1 copy number in the 
genome. Therefore, FAST-1 copy numbers were determined by 
quantitative TaqMan qPCR. Several aspects of epigenetics are strongly linked to 
non-coding RNAs. To investigate a potential explanation for the FAST-1 
overexpression effect on the FXN gene, epigenetic changes were studied at the FXN 
locus of the FAST-1 overexpressing cells. Several previous studies have 
demonstrated that specific histone modifications are strongly associated with FXN 
gene silencing. Therefore, chromatin immunoprecipitation (ChIP) was carried out 
using antibodies against the characteristic heterochromatin marker trimethylated 
histone 3 lysine 9 (H3K9me3) and euchromatin marker acetylated histone 3 lysine 9 
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(H3K9ac). It has been reported that there is a negative association between FAST-1 
expression and CTCF occupancy level at the FXN locus. In FRDA, higher levels of 
FAST-1 were associated with decreased CTCF binding at the 5′UTR of the FXN 
gene. On the other hand, global CTCF knockdown in normal cells was associated 
with increased level of FAST-1. In fact, after knocking down CTCF, FAST-1 levels in 
normal cells showed a corresponding doubling and were equalized to the level seen 
in FRDA (De Biase et al., 2009). To examine the effect of FAST-1 overexpression on 
CTCF occupancy, ChIP with anti-CTCF was performed on FAST-1 overexpressing 
HeLa cells. To complete the epigenetic studies on FAST-1 overexpressing cells, the 
DNA methylation profiles of FAST-1 overexpressing fibroblast cells were 
investigated. In this chapter, three non-FRDA FAST-1 stably-overexpressing cell 
lines were generated and the corresponding effects on FXN expression and 
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3.2 Materials and methods 
3.2.1 Cloning  
To overexpress FAST-1 in HEK293, HeLa and fibroblast cell lines, FAST-1 was 
cloned into a mammalian expression vector named pcDNA3 in which expression is 
driven by the human CMV promoter and it also contains a Geneticin® selectable 
marker. Previously in our laboratory, a full-length FAST-1 fragment was cloned into 
pCR™4-TOPO® vector by TOPO TA® cloning and then it was transformed into 
DH5α competent cells.  
3.2.1.1 Growth and maintenance of E. coli 
For long‐term storage, bacterial cultures were stored in 15% (v/v) glycerol at -80°C. 
Escherichia coli (E. coli) were grown in liquid LB media at 37°C with agitation at 250 
rpm. E. coli transformed with plasmid was grown overnight in 5ml LB medium 
containing 50μg/ml of ampicillin at 37°C with agitation at 250 rpm. Transformed cells 
were spread onto agar plates containing 50μg/ml of the relevant selective antibiotic. 
The plates were incubated overnight at 37°C, after which colonies were picked using 
sterile 20μl pipette tips and grown overnight in 5ml liquid LB cultures. The plasmids 
were purified by using QIAprep spin mini kit. 
3.2.1.2 Plasmid DNA purification using the QIAprep spin mini kit 
5ml bacterial cultures were harvested by centrifuging at 4K rpm (microfuge) for 5 
minutes at room temperature. The supernatant was discarded completely. Following 
vortexing, the pellet was resuspended in 250μl of P1 buffer (50mMTris-HCl, pH 8.0, 
10mM EDTA, 100μg/ml RNase A). The plasmid DNA was denatured by adding 
250μl of buffer P2 (200mM NaOH, 1% SDS). To neutralize the solution and re-
anneal the denatured DNA, 350μl of buffer N3 (4.2 M Gu-HCl, 0.9 m potassium 
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acetate pH 4.8) was added and mixed immediately. After centrifuging for 10 minutes 
at 13K rpm in a microfuge, the supernatant was transferred to QIAprep spin column. 
To remove trace nuclease activity, 500μl of PB buffer (5M GU-HCl, 30% isopropanol) 
was used to wash the column and followed by 60 seconds centrifuging. The column 
was washed again with 750μl of PE (10mm Tris-HCl, pH 7.5, 80% ethanol) and 
centrifuged for 60 seconds. To remove residual wash buffer, the empty column was 
centrifuged for an additional 60 seconds. To elute the DNA, 50μl of pre-warmed 
buffer EB (10mM Tris-Cl, pH 8.5) was added to the column and left to stand for 5 
minutes. Following centrifuging for 5 minutes, the purified plasmid DNA was 
collected in 1.5ml Eppendorf tube. 
3.2.1.3 Restriction enzyme digestion 
1μg of plasmid DNA was digested in a final volume of 20μl containing 1x buffer 
(supplied by the manufacturer) and the restriction enzyme. The volume of enzyme 
used varied depending of the concentration of the enzyme stock but did not exceed 
10% (v/v) of the total reaction volume. Reactions were carried out as the 
manufacturer’s instructions at the recommended temperature and duration. DNA 
digestion was verified by agarose gel electrophoresis.  
3.2.1.4 Purification of DNA fragments from agarose gels by using the 
GeanClean III Kit 
0.8% agarose mini-gels were prepared with a wide-toothed comb. Linearized vector 
and digested recombinant plasmid containing FAST1 (~20l) were run for 
approximately 2.5 hours at 75V in 1×TBE buffer. The desired bands were excised 
from the gel by a scalpel blade under 320nm wavelength UV light. After measuring 
the weight of excised bands, an approximate volume of gel slice was determined 
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(100mg=100l). 1/2 volume of TBE modifier and 4.5 volumes of NaI were added to 
the gel slices. Following 5 minutes incubation at 55°C in a water bath the gel slices 
were completely dissolved. According to the final volume of the mix, calculated 
volume of glassmilk was added to each sample and the samples were then 
incubated for 5 minutes at 55°C in a water bath with gentle inversion every 1 minute 
to resuspend the glassmilk. Following centrifuging for 5 seconds at 13K rpm, the 
pellets were washed 3 times by adding 250l of ‘new wash’ solution. The pellets 
were air-dried and then resuspended in 10l of elution buffer. Following centrifuging 
at high speed for 30 seconds, the purified DNA samples were collected and their 
concentration and purity was determined by a NanoDrop™ 2000c 
spectrophotometer. DNA concentration was determined by reading the absorbance 
at 260nm wavelength (A260). To assess the quality of DNA, the ratio of the 
absorbance at 260nm and 280nm (A260/280) was measured. A ratio of ~1.8 is 
accepted as pure DNA. 1l of gel purified plasmid and FAST-1 fragments were run 
on a 1% agarose gel (Figure 3.1). 




Figure 3.1: Gel purified pcDN A3 and FA ST-1.  
3.2.1.5 Dephosphorylating expression vectors  
To prevent recircularization of plasmid vectors, 2g of the gel purified linearized 
plasmid was dephosphorylated in a final volume of 30μl containing 1μl of CIP (calf 
intestinal alkaline phosphatase) and 3μl of 10xdephosphorylation buffer. The 
reaction was carried out for 30 minutes at 37°C in water bath. The reaction was 
stopped by adding 5mM EDTA and heating the tube at 85°C for 15 minutes. The 
DNA was extracted by the phenol/chloroform method. 
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3.2.1.6 DNA ligation 
A 1:2 molar ratio of vector to insert was used to clone the FAST-1 fragment into 20ng 
of vector. 1l of T4 DNA ligase and 2l of 5×ligase buffers were added to a final 
volume of 10l. Ligation reactions were incubated for 18 hours at 14°C. 
3.2.1.7 Transforming competent cells 
50μl of DH5α competent cells were transferred into pre-chilled Eppendorf tube (s). 
5μl of DNA was added to the cells and mixed gently. Following incubation on ice for 
30 minutes, the cells were subjected to a heat-shock at 42°C in a water bath, for 
exactly 20 seconds. The tube was then placed on ice for 2 minutes. 250μl of pre-
warmed (37°C) SOC (super optimal broth with catabolite repression) was added to 
cells. To let the transformed cells express the antibiotic resistance, cells were 
shaken at 220 rpm, 37°C, for 1 hour. 100μl of SOC containing transformed cells was 
spread on an agar plate containing 50mg/ml of a relevant antibiotic. The plate was 
incubated in a 37°C incubator overnight. 
3.2.1.8 Colony PCR screen 
To identify plasmids containing the insert DNA, colony PCR was performed. 
Individual transformants were picked by pipette tips and dipped into 10l sterile 
water. The tips were streaked on fresh agar plates containing the relevant antibiotic. 
To release the plasmid DNA from the cell, sterile water containing a transformant 
was heated to 98°C for 10 minutes. The mixture was used as a template for 
amplification reactions. Three primers were designed to determine the presence and 
correct molecular size of the insert (Table 3.1). 
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Table 3.1: List of primers used for colony screen 




















The pcDNA3-F/ pcDNA3-R primers were designed to produce an amplicon of 623bp 
only if the insert is present in the plasmid construct. In another PCR amplification, 
pcDNA3-F was paired with an insert specific primer (Insert-R) to produce an 
amplicon of 149bp only if the insert is in the correct orientation. 1l of 5mM forward 
primer, 1l of 5mM reverse primer, 6.25l of REDtaq ReadyMix PCR Reaction Mix 
(2×) (Sigma), 3.75l of PCR-grade water and 1l of heated transformed cells were 
added in a PCR tube. The PCR tube was centrifuged briefly and PCR was 
performed in a thermal cycler (Table 3.2). 
Table 3.2: Screen PCR program 
Step Temperature Time Cycles 
Initial 
denaturation 








30sec                          
1min and 30sec 
 
30 
Extension 72°C 1min 1 
 
To visualize the results, PCR products were run on a 1% agarose gels along with a 
1kb plus DNA size marker (Invitrogen) at 75V for ~45 minutes. Transformants that 
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produced both 623bp and 149bp amplicons were considered as positive clones 
which contain the FAST-1 insert in the correct orientation (Figure 3.2). To perform 
diagnostic restriction enzyme digestion, 5 positive clones were picked and grown in 
5ml LB and 5l ampicillin and shaken at 220 rpm in a 37°C incubator overnight. 
 
Figure 3.2: C olony PCR screen.  
3.2.1.9 Diagnostic restriction enzyme digestion 
The plasmid DNA was isolated from the overnight bacterial cell cultures using 
QIAprep spin Miniprep kit, and then 2ul of the DNA were incubated with EcoRI for 2 
hours at 37°C. To verify that the plasmid backbone and insert are of the expected 
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size, the digested plasmid was then run on a 1% agarose gel along with a 1kb plus 
DNA ladder (Figure 3.3). 
 
Figure 3.3: C olony PCR screen and d iagnostic restriction d igest.  
 
 





Plasmid DNA containing the FAST-1 insert and the pEGFP-C1 plasmid were 
prepared by using the EndoFree Plasmid Maxi Kit. To measure the transfection 
efficiency, pEGFP-C1 plasmid was co-transfected with test plasmid (pcDNA3/FAST-
1) into a separate well of HEK293 and HeLa cells. Mock-transfection was performed 
for both cell lines. Appropriate numbers of HEK293 and HeLa cells were seeded in a 
24-well plate to obtain 80% confluency on the day of transfection. Lipofectamine 
3000 (Life Technologies) was used as a DNA carrier for the transfection. 2l of the 
Lipofectamine 3000 was diluted in 50l of Opti-MEM I Reduced Serum Medium (Life 
Technologies) and 1.6g of DNA was mixed with 50l of Opti-MEM and 2l of P3000 
Reagent. The DNA-liposome complex was prepared by adding diluted DNA into 
diluted Lipofectamine and incubating for 5 minutes at room temperature. 50l of 
DNA-liposome mixture was added to each well containing cells. The cells were 
incubated at 37°C in a 5% CO2 incubator with 92-95% humidity for 5 hours. To 
reduce toxicity of Lipofectamine, after 5 hours the transfection media was removed 
and replaced with complete medium and incubated overnight at 37°C in a 5% CO2 
incubator. The following day, cells were trypsinised and transferred into 5ml 
complete medium and seeded in a 6-well plate in 1/5, 1/20 and 1/50 dilutions. Cells 
were incubated overnight at 37°C in a 5% CO2 incubator with 92-95% humidity. The 
following day, the media was aspirated and replaced with fresh DMEM containing 
the appropriate concentration of G418 antibiotic. The selection media was replaced 
every 3-4 days. According to the antibiotic kill assay, HeLa and HEK293 cells were 
selectable with 200g/ml and 400g/ml of G418, respectively.  




To measure the transfection efficiency, pEGFP-C1 plasmid was co-transfected with 
test plasmid (pcDNA3/FAST-1) into a separate well of fibroblast cells. One to two 
days prior to electroporation, cells were seeded in flasks with fresh growth medium 
to reach 70-90% confluency on the day of transfection. On the day of transfection, 
stable transfections of fibroblast cells were performed by using Neon™ transfection 
system. Cells were washed twice with PBS (-Mg+, Ca2+) and cell counts were 
performed after trypsinization. 106 cells were transferred into a 1.5ml microcentrifuge 
tube and cells were centrifuged at 400xg for 5 minutes at room temperature. The cell 
pellet was resuspended in 140μl of buffer R (provided with the kit) and 5μg of DNA 
was added to the mixture. The cells were picked up with the Neon™ pipette by using 
Neon™ tips and exposed to an electric current (1200V, 20ms, 2 pulses) in the 
Neon™ cuvette filled with 3ml of Buffer E (provided with the kit). After 
electroporation, samples were diluted 10-fold in 900μl medium. 100μl of the diluted 
samples were added to 1900μl pre-warmed culture medium. Cells were then left to 
grow in media without antibiotics for 24 hours. The following day, the GFP 
expression was visualised under a fluorescent microscope (Figure 3.4) and media 
was aspirated and replaced with fresh DMEM containing appropriate concentration 
of G418 antibiotic. The selection media was replaced every 3-4 days. According to 
the antibiotic kill assay, transfected fibroblast cells were selectable with 100g/ml of 
G418.  




Figure 3.4: The expression of GFP (green fluorescent  protein) in  fibrob last cells co-transfected with pcDN A3/FA ST-1 and pEGFP-C1 under a fluorescent microscope.  
3.2.3 Antibiotic kill curves 
 To determine the optimal antibiotic concentration for selecting stable colonies, 
antibiotic kill curves were determined. The appropriate numbers of cells were seeded 
in a 24-well plate to reach up to 20% confluency at the day of transduction. Cells 
were incubated overnight at 37°C, 5% CO2 with 92-95% humidity. The next day 
medium was replaced with complete medium containing antibiotic G418 ranging 
from 0-700μg/ml for HeLa and fibroblast cells and 0-1200μg/ml for HEK293 cells. 
The experiment was performed in triplicate for each cell line. The media containing 
selection antibiotic was replaced every 4 days. After 2 weeks, cells were trypsinised 
and suspended in DMEM. To determine the lowest concentration that causes 
complete cell death, cell viability was measured in different concentrations of G418. 
20μl of 0.4% (w/v) Trypan blue solution was added to 20μl of cell suspension and 
allowed to stand for 5 minutes. A small amount of Trypan blue-cell suspension 
mixture was transferred to a chamber port of Countess™ Cell Counting Chamber 
Slide (Invitrogen) and live and dead cells were counted by a Countess™ Automated 
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Cell Counter (Invitrogen). The lowest concentration which killed 100% of the cells 
was chosen as the optimal concentration.  
3.2.4 Overexpressing FAST-1 in non-FRDA cell lines 
To construct a FAST-1 delivery vector, full length FAST-1 transcript was inserted into 
the multiple cloning site of expression vector pcDNA3. The pcDNA3 plasmid is a 
mammalian expression vector with the CMV promoter and ampicillin resistance in 
bacteria and neomycin resistance in mammalian cells. FAST-1-pCRTM4-TOPO® 
and pcDNA3-containing E. coli bacteria were cultured overnight at 37°C in LB 
medium containing 50μg/ml ampicillin. Plasmids were purified using the QIAprep 
spin mini kit (section 3.2.1.2). To release the FAST-1 insert from the pCRTM4-
TOPO® vector and to linearise pcDNA3, both plasmids were digested by EcoRI and 
run on 0.8% agarose gel. Desired bands were cut out and purified using a 
GeanClean III Kit (section 3.2.1.4). The pcDNA3 vector was dephosphorylated and 
ligated with the insert (FAST-1). DH5αTM competent cells were transformed with 
ligation product and plated overnight on LB/AMP. Colonies were screened via PCR 
(section 3.2.1.8) and the presence of the insert was confirmed by restriction enzyme 
digestion (section 3.2.1.9). Once the presence and correct orientation of the FAST-1 
insert was confirmed, human HeLa, HEK293 and fibroblast cell lines were stably 
transfected with pcDNA3/FAST-1 (section 3.2.2). A GFP-tag plasmid was co-
transfected to check the transfection efficiency. The transfected cells were ells were 
put into G418 selection. In order to obtain a monoclonal cell population, limiting 
dilution method was performed. Two days after transfection, transfected HeLa and 
HEK293 cells were harvested and diluted 1/100 and 1/50 respectively. Cells were 
cultured in selective media for 5 days to expand. The culture dishes were examined 
under an inverted microscope. The well-isolated clones were found under the 
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microscope and a circle was drawn around each clone on the bottom of the culture 
dish. Then, cells were washed with PBS and picked by placing a drop of trypsin on 
each cell clone. The resistant single cell colonies were picked and further grown. 
Since fibroblast cells need secreted factors from their neighbouring cells to grow, 
they did not undergo this step. 12 stable FAST-1 overexpressing HeLa and HEK293 
cell lines and 3 stable FAST-1 overexpressing fibroblast cell lines were developed in 
selective media containing 200g/ml, 400g/ml and 100g/ml of G418, respectively. 
3.2.5 Quantification of FAST-1 and FXN mRNA levels in FAST-1 overexpressing 
cells 
Total RNA was isolated from FAST-1 overexpressing cells using the Trizol method. 
Once RNA samples were prepared, agarose gel electrophoresis was used to visually 
assess the quality of RNA samples. RNA concentration was measured by 
NanoDropTM 2000c spectrophotometry. To remove any residual gDNA, RNA 
samples were subjected to DNase I treatment (Invitrogen). DNase I-treated RNA 
was amplified using FAST F1 and FAST R1 primers (for FAST-1 cDNA) and PCR 
products were run on an agarose gel. Amplification of DNase I-treated RNA samples 
indicated that there was no gDNA contamination in the RNA samples. To synthesise 
cDNA, the cloned AMV first-strand cDNA synthesis kit was used as per the 
manufacturer’s instructions. Oligo (dT) and FAST-1-specific primer (FAST RT) were 
used for cDNA synthesis. To ensure that FAST-1 amplification was not from self-
priming, FAST RT primer was omitted from the cDNA synthesis mixture. In order to 
check if the cDNA synthesis had worked, the FAST-1 cDNA was amplified with the 
N-FAST F2 and FAST R1 primer set to produce an 88bp product. The oligo-dT-
primed FXN and HPRT cDNAs were amplified using FXN-h-F/R and HPRT-h-F/R 
primer sets respectively. The PCR products were run on a 2% agarose gel. In 
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samples without FAST RT primer, no PCR product was detected on the agarose gel, 
indicating that FAST-1 amplification was not a result of endogenous priming. The 
conditions and the PCR master mix components are shown in (Table 3.3). 
Table 3.3: FAST-1 cDNA PCR program 
 
2μl of the diluted synthesised cDNA was used as a template for qRT-PCR together 
with 8μl of the reaction mixture. The qRT-PCR experiment was run on standard 
program using a QuantStudio 7 Flex Real-Time PCR instrument (Applied 
Biosystems). The qPCR master mix components are shown in (Table 3.4). 









Power SYBR® Green             Power SYBR® Green  Power SYBR® Green 5 
N-FAST F2 primer(50μM)    
FAST-R1 primer(50μM)       
FXN-h-F primer(50μM) 
FXN-h-R primer(50μM)                   
HPRT-h-F primer(50μM) 
HPRT-h-R primer(50μM)                   
0.05 
0.05 
dH2O                                       dH2O dH2O 2.9 
cDNA (1:5) cDNA (1:10) cDNA (1:100) 2 
 
Step Temperature Time Cycles Components Volume(μl)/Reaction 
Initial 
denaturation 
95°C 30sec 1 Qiagen MasterMix (2X) 12.5  












N-FAST F2 primer(10μM) 




Extension 72°C 10mins 1 dH2o  3.5   
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3.2.6 TaqMan ® copy number assay  
TaqMan® copy number assays were run simultaneously with a TaqMan® copy 
number reference assay in a duplex real-time PCR. The copy number assay 
amplifies the target genomic sequence of interest and the reference assay amplifies 
a sequence that is known to exist in two copies in a diploid genome. A TaqMan® 
copy number reference assay (Applied Biosystems), RNase P forward and reverse 
primers and a TaqMan TAMRA™probe, and two custom designed TaqMan® copy 
number assays (Applied Biosystems), containing FAST-1-detecting forward and 
reverse primers and a TaqMan MGB probe, were used in this experiment. The 
master mix listed in (Table 3.5) was prepared. 
 
Table 3.5: Reaction mixture components and volumes 
Reaction mixture component  Volume per well (μl) 96-well plate  
TaqMan® Universal Master Mix II (Applied Biosystems)  
 
10.0 
TaqMan® Copy Number Assay, 20× working stock  
 
1.0 
TaqMan® Copy Number Reference Assay, 20×  
 
1.0 
Nuclease-free water  
 
4.0 




The following samples were run on each plate using four replicates for each gDNA 
sample:  
- Samples: gDNA samples in which the copy number of the target is unknown.  
- No Template Controls (NTC): A sample that does not contain a DNA 
template, used for the detection of contamination and background 
fluorescence.  
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- Calibrator sample: A DNA sample with a known copy number for the target 
of interest.  
16μl of the reaction mixture was added into each well of a MicroAmp® Fast Optical 
96-well Reaction Plate (Applied Biosystems). The diluted gDNA samples were 
vortexed and spun briefly before adding to the plate. 4μl of gDNA (5ng/μl) was added 
to the wells containing the reaction mixture. The reaction mixture and gDNA were 
mixed by pipetting up and down for several times. The reaction plate was sealed with 
MicroAmp® Optical Adhesive Film (Applied Biosystems) and centrifuged briefly. The 
reaction plate was loaded into a QuantStudio 7 Flex Real-Time PCR instrument 
(Applied Biosystems) and a standard program was run. The number of FAST-1 
copies in each genomic DNA sample was determined by relative quantitation (RQ) 
normalized to the known copy number of the reference sequence using the 
comparative Ct (ΔΔCt) method and the Ct data were subsequently compared to a 
calibrator sample (non-FAST-1 transfected cells) known to have two copies of FAST-
1 sequence, analysed by Applied Biosystems CopyCaller™ Software v.2.0. The 
predicted copy number values were calculated by rounding up the actual copy 
number values. TaqMan ® Copy Number Assay requires two target specific primers 
and a probe which anneals to its complementary sequence between forward and 
reverse primers. TaqMan probes are covalently joined to a reporter dye at their 5' 
ends and a quencher dye at their 3′ ends. When the quencher is in the close 
proximity to the reporter, no increase in fluorescent signal from the reporter dye can 
be detected. During each round of PCR, Taq DNA polymerase, which has 5' 
exonuclease activity, cuts the probe and physically separates the reporter from the 
quencher dye. This creates a permanent increase in fluorescence of the reporter 
dye. QuantStudio 7 Flex Real-Time PCR instrument (Applied Biosystems) can 
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monitor and record this increase in fluorescence and generate an amplification plot 
(Figure 3.5). 
 
Figure 3.5: PCR and  det ection of target  and  reference gDN A sequences in a dup lex reaction.  
3.2.7 MethylScreen assay 
DNA methylation analysis was performed using the previously described 
MethylScreen assay (Al-Mahdawi et al., 2013). This technique uses combined 
restriction digestion of DNA with a methylation-sensitive restriction enzyme (MSRE) 
and methylation-dependent restriction enzyme (MDRE) as both single and double 
digests (Figure 3.6). The MethylScreen assay was used to analyse the FXN U6 and 
U11 CpG regions (Figure 3.7). Genomic DNA was extracted by the 
phenol/chloroform method and 0.5µg of each sample was used in each of four tubes, 
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for four different restriction enzyme digestions: (1) a MSRE, (2) a MDRE, (3) both 
MSRE and MDRE (double digest, DD), and (4) neither MSRE or MDRE (mock 
control). The digestion reaction components are shown in (Table 3.6 and 3.7).  
 
Figure 3.6: Overview of the MethylScreen t echnology procedure performed  at the FXN CpG6 (U6) and C pG11 (U11) sites.  
 
Figure 3.7: FXN reg ion of M ethylScreen analysis.  
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Table 3.6: U11 MethylScreen digestion reactions components 
Components Volume  AjiI McrBC Double Digest Mock 
0.5μg DNA 5μl         
AjiI (5U/μl)  2μl       
McrBC (10U/μl) 1μl       
10 X TANGOTM  10μl         
GTP (100mM) 1μl       
50% Glycerol 3μl      
Each reaction was made up to 100ul with dH2O 
Table 3.7: U6 MethylScreen digestion reactions components 
Components Volume  Hpy188III McrBC Double Digest Mock 
0.5μg DNA 5μl         
Hpy188III (10U/μl)  1μl       
McrBC (10U/μl) 1μl       
10 X TANGOTM  10μl         
GTP (100mM) 1μl       
50% Glycerol 3μl      
Each reaction was made up to 100ul with dH2O 
For site U11, AjiI (Fermentas) and McrBC (Fermentas) were used respectively as the 
MSRE and MDRE, respectively. For site U6, Hpy188III (New England Biolabs) and 
McrBC (Fermentas) were used respectively as the MSRE and MDRE respectively. 
The digestion reactions were carried out for 16 hours at 37°C in water bath. The 
reactions were stopped and enzymes were deactivated by heating the tubes at 65°C 
for 20 minutes. Samples were then placed on ice and briefly centrifuged to collect 
contents at the bottom of the tubes. To check the efficiency of digestion reactions, 
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5μl of each reaction was run on a 1% agarose gel. 5μl of DNA was used as a 
template for qPCR together with 15μl of the reaction mixture. Real-time PCR was 
performed in triplicate using a QuantStudio 7 Flex Real-Time PCR instrument 
(Applied Biosystems). Each qPCR reaction was carried out in triplicates in a 20µl 
reaction volume by using 500ng of the digested DNA, 10µl of Fast SYBR Green 
(Applied Biosystems) and 1µl of 5µM each of the respective forward and reverse 
primers (see Table 3.8 for primers used). The MSRE enzymes selectively digested 
DNA at unmethylated cytosine residues and left the fully methylated DNA intact. 
Therefore, in MSRE digested samples, the amplified products were generated from 
the fraction of fully methylated DNA. In contrast, MDRE enzymes cut DNA at 
methylated cytosine residues. Because methylated DNA was fully digested by 
MDRE, the amplified products in qPCR represented the fraction of unmethylated 
DNA. In double digested tubes, where DNA was digested by both MSRE and MDRE, 
full digestion and no PCR amplification were expected. In principle, no digestion 
should occur in mock control and the lowest Ct values belonged to the undigested 
controls (Figure 3.8). Therefore, Fmet and Rmet primers produced an amplicon of 
196bp in the U11 mock control and a 160bp product was expected in the U6 mock 
control. PCR quantification was carried out using the ΔCt method (values were 
calculated as 2 ΔCt (mock-digest) with the mock value set at 100%) and RQ Manager 
Software (Applied Biosystems). MethylScreen DNA methylation values were then 
calculated as follows: Densely methylated DNA (DM)=(MSRE-DD)/(100-DD)×100; 
unmethylated DNA (UM) = (MDRE-DD)/(100-DD)×100; intermediately methylated 
DNA (IM) = 100–(DM+UM). 
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Table 3.8: Primer used in MethylScreen studies 
Primer name Sequence (5'-3') Amplicon size 
Fmet 















Figure 3.8: A t yp ical qPCR  amplification p lot of M ethylScreen .  
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3.3 Results  
3.3.1 Quantification of FAST-1 levels in FAST-1 overexpressing cells 
As described in section 3.2.4, twelve stable FAST-1 overexpressing HeLa cell lines, 
twelve stable FAST-1 overexpressing HEK293 cell lines and three stable FAST-1 
overexpressing fibroblast cell lines were developed. To confirm FAST-1 
overexpression in FAST-1 transfected cells, qRT-PCR measurements were 
performed as previously described in section 3.2.5, using primers designed to detect 
human-specific frataxin antisense transcript, FAST-1. Total RNA was isolated from 
stably overexpressing FAST-1 cells, and treated with DNase I and converted into 
cDNA. The resultant cDNA was used as a template in qRT-PCR reactions. To 
quantify FAST-1 expression the cDNA synthesised by FAST RT primer was diluted 
1:5 and used in qRT-PCR reactions; whereas for FXN and HPRT expression cDNA 
synthesised by oligo (dT) primer was diluted 1:10 and 1:100 respectively and used 
as qRT-PCR template. All the Ct values obtained for FAST-1 and FXN were 
normalised to the endogenous control gene HPRT, then calibrated to normal cells 
before transfection and the mean of control was set to 100%. Analysis of qRT-PCR 
measurement confirmed a very significant increase of FAST-1 expression in 
transfected HeLa cells (396%, P<0.001), transfected HEK293 cells (660%, P<0.05) 
and transfected fibroblast cells (332%, P<0.01) compared with non-transfected 
control cells (Figure 3.9). 




Figure 3.9: R elative FAST- 1 expression  in FA ST-1 overexpressing  cells.  
3.3.2 Quantification of FXN mRNA levels in FAST-1 overexpressing cells 
To assess the effect of FAST-1 overexpression on FXN mRNA expression, qRT-
PCR measurements were performed as previously described in section 3.2.5 using 
primers designed to detect human FXN cDNA. QRT-PCR analysis of FAST-1 
overexpressing cells revealed a very significant reduction of FXN mRNA in the 
FAST-1 overexpressing HeLa cells (45%, P<0.05), HEK293 cells (47%, P<0.001) 
and fibroblast cells (42%, P<0.001) compared with non-transfected control cells. To 
examine if the transfection reagents or the transfection process itself has any effects 
on the FXN expression in target cells, FXN mRNA levels were measured in empty 
vector-transfected samples. There was no significant difference detected between 
the empty vector-transfected and non-transfected control cells (Figure 3.10). 




Figure 3.10: R elative FXN mRN A expression in FA ST-1 overexpressing  cells.  
3.3.3 Determination of FAST-1 copy number in FAST-1 overexpressing cells 
To determine the copy number of FAST-1 integrated into the genome, ~20 ng 
samples of genomic DNA from FAST-1 overexpressing HeLa cell lines were 
analysed by TaqMan qPCR copy number assay. To assess the reliability of each 
copy number call, the results were analysed by Applied Biosystems CopyCaller™ 
Software v.2.0. Eight out of twelve FAST-1 overexpressing HeLa cell lines had 
acceptable confidence values and absolute zero score (<2.65) to pass the test. As 
previously described in section 3.2.6, duplexed TaqMan reactions were applied to 
accurately quantitate the level of FAST-1 in FAST-1 overexpressing cells relative to 
the endogenous reference gene RNase P. RNase P was known to have two copies 
in a diploid genome. Non-transfected cells known to have two copies of FAST-1 
were used as the calibrator samples. Results from the TaqMan assay indicated that 
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there was a significant positive correlation between FAST-1 copy number and FAST-
1 expression (R =0.7, P<0.05) (Figure 3.11). 
 
Figure 3.11: TaqMan copy number assay to determine the FA ST-1 copy number in FA ST-1 overexpressing clones.  
Scatter plot analysis was conducted between FXN and FAST-1 expression for the 
FAST-1 overexpressing HeLa cells, revealing a strong negative correlation between 
FAST-1 expression and FXN expression (R = -0.58, P<0.05) (Figure 3.12). 




Figure 3.12: Scatter  plot of FXN mRN A expression  lev el v ersus FAST- 1 expression in FA ST-1 overexpressing HeLa cells.  
3.3.4 Quantification of FXN protein levels in FAST-1 overexpressing cells 
To determine the levels of human frataxin protein expression in the FAST-1 
overexpressing cells, the Frataxin Protein Quantity Dipstick lateral flow 
immunoassay assay was performed as described in section 2.4.13. Non-transfected 
cells were used as the controls in this experiment. All frataxin expression levels 
obtained from the FAST-1 overexpressing cells were calibrated to non-transfected 
control cells and the mean of control was set to 100%. The experiment was 
performed in triplicates. Results from these experiments demonstrated that frataxin 
protein expression was significantly decreased by 40% (P<0.01) in FAST-1 
overexpressing HeLa cells, 55% (P<0.05) in FAST-1 overexpressing HEK293 cells 
and 58% (P<0.001) in FAST-1 overexpressing fibroblast cells compared with non-
transfected control cells (Figure 3.13). 
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Figure 3.13: R elative frataxin  prot ein expression  in FAST- 1 over expressing cells.  
3.3.5 Investigation of histone modifications in FAST-1 overexpressing HeLa 
cells 
Measuring frataxin mRNA and protein expression before and after FAST-1 
overexpression in 3 different cell lines, HeLa, HEK293 and fibroblast, demonstrated 
that FAST-1 overexpression exerted a negative impact on the FXN gene expression. 
To investigate potential explanation for the effects of FAST-1 overexpression on FXN 
gene expression, specific histone modifications were studied in FAST-1 
overexpressing HeLa cells. Three different FAST-1 overexpressing HeLa colonies, 
which showed the lowest level of FXN expression, empty vector-transfected cells 
and a non-transfected HeLa cells were utilized in this experiment. Acetylated and 
trimethylated histone H3K9 modifications were investigated by ChIP analysis at the 
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FXN 5′UTR region. The ChIP procedure was performed as previously described in 
section 2.4.14. Real-time PCR was performed in triplicate in a final volume of 10μl 
containing 12.5pmol of each of the respective forward and reverse primers (see 
Table 2.6 for primers used). The ChIP results were normalized to input and -Ab 
values were taken into account. ChIP assay results showed significantly decreased 
acetylation of H3K9 at the FXN 5′UTR region in FAST-1 overexpressing HeLa cells 
compared to non-transfected control cells. There were no statistically significant 
differences in H3K9 acetylation levels between the empty vector-transfected and 
non-transfected control cells (Figure 3.14). 




Figure 3.14: Ch IP with anti-H 3K9ac in  FAST- 1 overexpressing H eLa cells.  
In addition, significant enrichment of H3K9me3 was detected at the 5′UTR of the 
FXN gene (Figure 3.15). H3K9me3 enrichment was determined by subtracting the 
respective minus antibody samples from the H3K9me3-precipitated samples, 
followed by normalisation to the input sample.  




Figure 3.15: Ch IP with anti-H 3K9me3 in FA ST-1 overexpressing H eLa cells.  
3.3.6 Determination of CTCF levels in FAST-1 overexpressing HeLa cells 
It has previously been reported that CTCF depletion results in increased FAST-1 
transcription. To elucidate the relationship between CTCF and FAST-1 in FAST-1 
overexpressing HeLa cells, ChIP experiments were performed with an anti-CTCF 
antibody. CTCF ChIP analysis revealed that CTCF occupancy was decreased 
sharply at the 5′UTR of the FXN gene. In addition, comparison of CTCF occupancy 
in empty transfected-vector and non-transfected HeLa control cells did not show a 
similar reduction (Figure 3.16). 




Figure 3.16: Ch IP with anti-CTCF in FA ST-1 overexpressing  HeLa cells.  
3.3.7 Investigation of DNA methylation in FAST-1 overexpressing fibroblast 
cells 
It has been reported that CpG U6 and CpG U11 show elevated levels of DNA 
methylation in FRDA patients compared to controls (Greene et al., 2007; Al-Mahdawi 
et al., 2013). Therefore, MethylScreen technology was used to determine the level of 
DNA methylation at CpG U6 and CpG U11 in two FAST-1 overexpressing fibroblasts 
cell lines (FAST-1B, FAST-1C), together with FRDA fibroblasts and unaffected 
control fibroblasts. Results from MethylScreen assays revealed a non-significant 
small increase in DNA methylation at CpG site U6, with DM values increasing from 
14% in unaffected control fibroblasts to 18% and 23% in FAST-1 B and FAST-1 C, 
respectively (Figure 3.17).  




At CpG site U11, the proportion of densely methylated templates in FAST-1 
overexpressing fibroblasts significantly increased from 8% in unaffected controls to 
79% (P<0.01) and 76% (P<0.001) in FAST-1 B and FAST-1 C, respectively, similar 
to the levels found in FRDA fibroblasts (Figure 3.18). 
 
Figure 3.17: DN A methylation  lev els in  FAST-1 ov erexpressing fib roblast s analysed by M ethylScreen  technique.  














It is well established that the GAA repeat expansion results in decreased 
transcription of the FXN gene and the protein it codes for. Despite extensive 
investigation, the exact FRDA disease mechanisms remain unknown. However, it 
has been reported that the FAST-1 expression levels were two-fold higher in FRDA 
patient-derived fibroblasts. Therefore, to investigate potential FAST-1 effects on FXN 
expression, we stably overexpressed FAST-1 in HeLa, HEK293 and fibroblast cells. 
QRT-PCR analysis confirmed FAST-1 overexpression in all three cell lines. Analysis 
of frataxin mRNA expression revealed a significant reduction in the levels of the FXN 
transcripts in FAST-1 overexpressing cells. Measuring frataxin protein expression 
levels by lateral flow immunoassay demonstrated that FAST-1 overexpressing cells 
also express significantly less frataxin protein compared to control cells. In addition, 
no significant FXN gene and protein expression changes were detected in empty 
vector control cells. These results indicate that FAST-1 can act in trans in a similar 
manner to the cis-acting FAST-1 overexpression that has previously been identified 
in FRDA fibroblasts. Additionally, we identified a significant positive correlation 
between FAST-1 copy number and FAST-1 expression level (R=0.7, P<0.05) and a 
negative correlation between FAST-1 copy number and FXN expression level (R=-
0.58, P<0.05). This suggests a concentration-dependent molecular mechanism of 
action for FAST-1, rather than a potential threshold effect. To investigate the 
potential mechanisms for the FAST-1 overexpression effects, two major epigenetic 
modifications, DNA methylation at the CpG sites U6 and U11 and histone 
modifications at the promoter region of the FXN gene in FAST-1 overexpressing 
cells, were studied. FAST-1 overexpressing cells showed reduced FXN expression 
levels and exhibited similar epigenetic changes to those observed in FRDA cells. 
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FAST-1 overexpressing HeLa cells showed reduced occupancy of CTCF, a 
decreased level of H3K9ac and an increased level of H3K9me3 at the 5′UTR of the 
FXN gene. Several studies suggest that antisense RNAs might be key regulators in 
gene expression. There are various potential ways by which antisense RNA 
involvement could cause heterochromatin formation and epigenetic silencing of the 
partner gene. Studies suggest that aberrantly expressed antisense RNA mostly act 
at the RNA level to epigenetically silent their corresponding sense genes (Whitehead 
et al., 2009; Kanduri, 2011). Antisense RNAs can act as scaffold or directly recruit 
chromatin modifying proteins to chromatin. Antisense RNAs such as Xist, Kcnq1ot1, 
which is expressed from intron 10 of the imprinted gene Kcnq1, and HOTAIR can 
recruit DNA and chromatin modifying proteins, such as the PRC2 complex, which 
has H3K27 methyltransferase activity and catalyses heterochromatin formation and 
gene repression (Zhao et al., 2008; Khalil et al., 2009; Marchese and Huarte, 2014). 
The enrichment of H3K9me3, H3K27me3 and HP1 at the 5′UTR of the FXN gene 
have previously been observed and we also detected H3K9me3 enrichment and 
reduced H3K9ac and frataxin expression following FAST-1 overexpression in non-
FRDA HeLa cells (Al-Mahdawi et al., 2008; De Biase et al., 2009; Kim et al., 2011). 
Therefore, it is plausible to speculate that FAST-1 may induce RNA-dependent 
histone modification and promote the heterochromatinisation of the FXN gene.  
In addition, it has been reported that the FAST-1 transcript may form a double-
stranded RNA with the FXN sense transcript and the resulting RNA duplex may 
interact with argonaute proteins, Ago1 and Ago2, which are key players in RNA-
induced transcriptional gene silencing (RITS). Strikingly, knocking down Ago1 and 
Ago2 in FRDA cells reversed the repressive chromatin at the 5′UTR of the FXN gene 
(Bidichandani et al., 2011). Moreover, some studies suggest that antisense 
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transcripts can recruit Ago proteins during gene silencing (Chu et al., 2010; Schwartz 
et al., 2014). Based on these findings and our own observations, it can be suggested 
that FAST-1 overexpression may trigger an RNA interference (RNAi) pathway, 
causing the establishment of heterochromatin in the 5′UTR of the FXN gene. 
However, some studies argue against a role for RNAi system in FRDA, as the 
authors reported that they could not detect small interfering RNAs (siRNAs) 
matching the FXN locus (Punga and Bühler, 2010). Presently, none of the above 
possibilities can be ruled out and further studies are required. The effects of stably 
transfected FAST-1 overexpression on CTCF and H3K9ac and H3K9me3 at the FXN 
5′UTR locus indicate a potential causative role for FAST-1 in FRDA, as opposed to 
the increased FAST-1 expression that is observed in FRDA merely being the passive 
result of loss of CTCF binding at the FXN 5′UTR. Thus, it is plausible that increased 
FAST-1 RNA molecules either directly displace CTCF from the FXN 5′UTR, or trigger 
heterochromatin formation in the FXN 5′UTR, which consequently results in CTCF 
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Natural antisense transcripts (NATs) are prevalent in the human genome. Although 
they generally have very low levels of expression, they have been shown to be 
involved in epigenetic silencing of their associated sense gene. Therefore, inhibition 
of NATs may lead to upregulation of the sense genes. It has been reported that 
suppression of antisense transcripts to p21 (Morris et al., 2008), BDNF (Brain-
Derived Neurotrophic Factor), GDNF (Glial-derived Neurotrophic Factor), EphB2 
(Ephrin receptor B2) (Modarresi et al., 2012b) and Oct-4 (octamer-binding 
transcription factor 4) (Hawkins and Morris, 2010) upregulates the corresponding 
mRNAs. We hypothesized that knocking down FAST-1 as an epigenetic modulator 
may increase FXN expression, therefore, FAST-1 was stably knocked down by short 
hairpin RNA (shRNA) in FRDA fibroblast cells and the subsequent consequences on 
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4.2 Material and methods 
4.2.1 Transduction of fibroblast cells 
Fibroblasts from healthy subjects (GM07492) were obtained from Coriell Cell 
Repository. The FRDA fibroblasts (FA1) were obtained from Dr Alexandra Durr (ICM 
University Hospital Pitié-Salpêtrière, Paris, France). Expanded GAA alleles for the 
FRDA patient were 416 & 59 triplets (FA1). To knock down FAST-1, Sigma custom 
cloning MISSION shRNA team designed a short hairpin RNA, cloned it into a 
pLKO.1-puro-CMV-tGFP vector and provided us with ready to use lentiviral particles 
for transduction. To ensure that the introduction of lentiviral particles and shRNA did 
not affect gene expression and that the observed outcomes were due to FAST-1 
silencing, a scrambled shRNA (pLKO.1-puro Non-Target shRNA Control 
Transduction Particles) was used. Human FRDA cells and non-FRDA fibroblast cells 
were grown in 6-well plates to reach 80% confluency. On the day of transduction, 
cells were rinsed with warm PBS and replaced with 500μl of fresh medium. To 
increase the lentiviral transduction efficiency, polybrene (8μg/ml) was mixed with 
FAST-1 and scrambled LV particles and added to the cells on a plate. To increase 
the contact surface between viral particles and cells, a minimum volume (500μl) of 
medium was added. Cells were incubated at 37°C and 5% CO2 for 6 hours and then 
the supernatant was replaced with 1ml fresh medium and incubated at 37°C and 5% 
CO2 for 72 hours to allow time for the expression of the reporter and puromycin 
resistance genes. After 72 hours, the selective antibiotic, puromycin, was added to 
the media at a final concentration of 0.2μg/μl. The selection media was replaced 
every 3 days and the final cell harvest for RNA analysis was performed at 2 weeks 
post-transduction. A lower concentration of puromycin was continued throughout the 
duration of the cell culture. 
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4.2.2 Determination of MOI for the transduction of the FRDA fibroblasts 
5x104 human FRDA fibroblasts that were growing exponentially were seeded into 6-
well plates and incubated for 18-20 hours at 37°C and 5% CO2. Triplicate wells of a 
6-well plate were used for each range of multiplicity of infection (MOI) and a control. 
Cells were washed with PBS and 500μl of fresh medium containing 8μg/ml of 
polybrene was added to each well, then an appropriate volume of the LV FAST-1-
GFP (5.7X107 TU/ml) (25μl-100μl) was added to each well to achieve a MOI of 5, 10, 
15 and 20. Cells were incubated at 37°C and 5% CO2 with viral supernatant for 6 
hours and then the supernatant was replaced with 1ml fresh medium and incubated 
at 37°C and 5% CO2 for 72 hours to allow time for the expression of the reporter and 
puromycin resistance genes. After 72 hours, puromycin antibiotic was added to the 
media at a final concentration of 0.2μg/μl. 
Following transduction of human FRDA fibroblasts, live cells were counted using 
trypan blue (Fisher Scientific). ImagestreamX was used to measure the number of 
the GFP-positive cells. In this method, cells were trypsinised and pelleted by 
centrifugation at 5000xg for 5 minutes at 4°C. The pellet was washed with ice-cold 
PBS and fixed with 4% paraformaldehyde for 3 minutes on ice. Fixed cells were 
washed with PBS and the pellet was resuspended in 100μl of Accumax and 1μl Draq 
5 was added to the cells. Cells were put through imaging flow cytometry using the 
ImagestreamX system (Amnis Inc.). Images of approximately 10,000 cells were 
captured on channel 1 for bright field (BF); on channel 2 for GFP representing the 
green GFP expression; and on channel 5 for the far-red DRAQ5™ staining of the 
nuclear region of each cell. Following excitation with a 488nm laser at a power 
setting of 70 mW, all images were captured using a 40xobjective (Figure 4.1). 
 




Figure 4.1: Flow cytometric imaging of FRD A fib roblast s.  
4.2.3 Aconitase activity  
The Aconitase Assay Kit (Cayman, 705502) was used to assess the aconitase 
activity of transduced FRDA fibroblasts. Cells were washed with cold PBS, scraped 
off the flask in ice cold PBS and centrifuged at 800xg for 10 minutes at 4°C. Pellets 
were resuspended in 50μl of cell lytic buffer and incubated on ice for 15 minutes. 
Lysates were centrifuged at top speed for 10 minutes at 4°C and used immediately. 
Samples were diluted in 1Xassay buffer (provided with the kit) to make a final 
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concentration of 0.5μg/μl in 200ul volume. 50μl of fresh cell lysate (0.5μg/μl), 
NADP+, isocitrate dehydrogenase and diluted Substrate Solution (all provided with 
kit) were added to each well of a 96-well plate and incubated at 37°C for 15 minutes 
in the dark. The absorbance at 340nm was measured once every minute with 5 
seconds mix time for 15 reads at 37°C using a Biorad xMark plate reader. The 
aconitase activity was determined from the slope of a graph by plotting the 
absorbance value over time. Since total cell lysates were used for this assay, 
aconitase activities of cells were then normalized to citrate synthase activities, which 
were determined using a citrate synthase assay kit (SIGMA, CS0720) according to 
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4.3 Results  
4.3.1 FAST-1 knockdown validation 
To achieve a stable FAST-1 knockdown, FRDA and normal fibroblast cell lines were 
transduced with lentiviral (LV) vectors expressing shRNAs targeting FAST-1 
(pLKO.1-puro-CMV-tGFP). Several precautions were taken in order to control off-
target effects and specificity, as follows: (i) pLKO.1-puro Non-Target shRNA was 
used as the negative control; (ii) The normal fibroblast cell line was also transduced 
with LV FAST-1 to assess the specificity of any FAST-1 knockdown effect on FRDA 
cells. 
After 10 days of puromycin selection, total RNA was extracted from the transduced 
cells and FAST-1 cDNA was synthesized using cloned AMV first-strand cDNA 
synthesis kit (Invitrogen) as previously described (section 2.4.5). The efficacy of 
shRNA knockdown was assessed by qRT-PCR. Analysis of FAST-1 expression 
levels in the FAST-1 knockdown control and FRDA fibroblast cell lines revealed that 
FAST-1 levels decreased to 63% (P<0.01) and 43% (P<0.01) respectively (Figure 
4.2). 




Figure 4.2: Quantitativ e RT-PCR  analysis of FA ST-1 expression levels in FA ST-1 knockdown fibrob last  cells.  
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4.3.2 Measurement of FXN expression levels following transduction of FRDA 
fibroblast cells with LV FAST-1 
After confirming efficient FAST-1 knockdown in FRDA fibroblast cells, FXN mRNA 
expression was measured in FAST-1 knockdown cells. Results from qRT-PCR 
analysis revealed that the levels of FXN expression in FAST-1 knockdown FRDA 
cells had increased by 1.5-fold (P<0.05) when compared to FRDA fibroblast cells. In 
contrast, FXN expression in normal fibroblast cells treated with LV FAST-1 showed a 
non-statistically significant 0.8-fold decrease in the FXN expression. FXN expression 
remained unchanged in FRDA fibroblast cells treated with scrambled control shRNA 
(Figure 4.3). 
Figure 4.3: Quantitativ e RT-PCR  analysis of FXN expression lev els in  control and FA ST-1 knockdown cell l ines. 
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4.3.3 Restoring aconitase activity following knockdown of FAST-1 
As a biomarker of frataxin function within cells, aconitase activity was measured in 
FAST-1 knockdown fibroblast cells 1 month after treatment with LV FAST-1 using 
the Aconitase Assay Kit (Cayman) as previously described in section 4.2.3. Normal 
FRDA fibroblast cells (GMO7492) and FRDA cells treated with scrambled shRNA 
were used as the controls. All data was calibrated to the mean of the aconitase 
activity in normal fibroblast cells, which was set to 100%. The aconitase activity in 
FRDA cells was determined to be 49% (P<0.05) compared to normal control 
fibroblast cell levels. However, after knocking down FAST-1 in FRDA fibroblast cells, 
aconitase activity significantly increased to a value of 195% (P<0.01). No significant 
difference was detected in FRDA fibroblast cells treated with scrambled shRNA 
(Figure 4.4).  
Figure 4.4: Acon itase activit y levels in control and  FAST- 1 knockdown
 cell  lines
  




Our understanding of antisense transcript biological functions and roles in gene 
expression regulation is not yet complete. Different high-throughput studies that have 
investigated sense and antisense transcription correlations have come to differing 
conclusions. Some studies suggest inversely correlated expression patterns 
between sense and antisense transcripts; while other studies report only weak 
inverse correlations (Alcid and Tsukiyama, 2014; Murray et al., 2015; Huber et al., 
2016). Furthermore, a recent study inhibited antisense transcription of 162 genes in 
S. cerevisiae and investigated its impact on gene expression. They observed 
antisense-dependent gene regulation in one quarter of the studied genes. They also 
found that antisense regulation was correlated with antisense transcription 
overlapping the sense TSS (Huber et al., 2016). Recently four highly conserved 
chromatin remodelling complexes were identified in S. cerevisiae, which directly 
repress antisense RNAs. Repression of these antisense RNAs are crucial for normal 
levels of mRNA transcription and their derepression leads to decreased sense 
mRNA levels (Alcid and Tsukiyama, 2014). With regard to FRDA, FAST-1 
transcription has been shown to overlap with the FXN TSS and have an inverse 
correlation with the FXN gene expression levels (De Biase et al., 2009; Sandi and 
Pook, 2015). As described in chapter 3, overexpression of FAST-1 in non-FRDA 
cells was shown to result in decreased FXN expression, suggesting that FAST-1 
might be involved in the modulation of the FXN epigenetic status, inducing 
heterochromatin formation and FXN gene silencing. The next step in answering our 
research question ‘does FAST-1 have a role in the molecular mechanisms of FRDA 
disease?’ was to knock down FAST-1 in FRDA fibroblast cells. To target FAST-1 
transcripts, we used shRNA lentiviral particles to transfect FRDA fibroblasts. 
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Knocking down FAST-1 in FRDA fibroblast cells resulted in a 57% reduction in the 
level of FAST-1 transcript expression and it was accompanied by 1.5-fold increase in 
the FXN transcript expression level. Not surprisingly, FXN expression did not show 
complete rescue to the same level as control fibroblast cells, because the expanded 
GAA repeat was still present in the cells. Indeed, targeting antisense RNAs has been 
shown to upregulate the expression of sense transcripts. Antisense non-coding RNA 
in the INK4 locus (ANRIL) is an antisense transcript whose increased expression 
level is associated with p14ARF, p15INK4b and p16INK4a silencing via direct interaction 
with both polycomb repressive comlex-1 and -2. Knocking down ANRIL leads to a 
significant increase in p14ARF, p15INK4b and p16INK4a transcripts (Yap et al., 2010; Li 
and Chen, 2013; Wan et al., 2013). Knocking down of antisense transcripts to p21, 
BDNF, GDNF, EphB2 (Modarresi et al., 2012b) and Oct-4 (Hawkins and Morris, 
2010) upregulates the corresponding mRNAs. Suppression of the p21 antisense 
transcript was followed by increased p21 sense transcript and loss of the 
suppressive H3K27me3 mark at the p21 promoter (Morris et al., 2008). Several 
studies suggest antisense RNAs can recruit PCR2 complex and direct gene 
silencing (Zhao et al., 2010). Thus, it can be speculated that inhibiting FAST-1 
transcript may reduce the heterochromatin repression and allow access to 
transcription factors to increase the FXN transcript expression. 
Aconitase enzyme activity is considered to be a good indicator of frataxin function 
within cells, such that low levels of mitochondrial frataxin are associated with 
reduced activity of the Fe-S containing enzyme aconitase (Bulteau et al., 2004). A 
recent study demonstrated that FXN gene delivery to FRDA cells resulted in long-
term overexpression of FXN mRNA and frataxin protein. The increased frataxin 
expression in FRDA cells restored aconitase enzyme activity to near normal levels 
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(Khonsari et al., 2016). Because our results of the FAST-1 knockdown study 
demonstrated an increase in the FXN expression level, we decided to investigate the 
aconitase activity in the FAST-1 knockdown FRDA cells. We showed that knocking 
down FAST-1 in FRDA cells resulted in a significant increase (from 49% to 195%) in 
aconitase activity. In the future, investigating the histone modification profiles and 
CTCF occupancy at 5′UTR of the FXN locus in FAST-1 knockdown cells may further 
help us to elucidate the role of FAST-1 in FRDA. 
















Chapter 5: Quantification of FAST-1 expression in 
the YG8LR FRDA mouse model   
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 5.1 Introduction 
To understand the exact molecular mechanisms of FRDA disease and to test 
potential therapies, developing mouse models is considered essential. Pook and 
colleagues have previously generated several human FXN YAC transgenic mouse 
models: Y47R, containing normal-sized GAA repeats (9), and YG8R and YG22R 
containing expanded GAA repeats (90+120 and 120, respectively). A novel line of 
mice, designed YG8sR and containing a single FXN transgenic locus with 120 GAA 
repeats has subsequently been derived from YG8R mice. FAST-1 expression was 
previously investigated in fibroblasts and neural stem cells (NSCs) derived from 
these YAC transgenic mouse models (Y47R, YG8sR, YG8R and YG22R). QRT-PCR 
analysis of fibroblast cells detected increased levels of FAST-1 in YG8R and YG22R 
mouse models compared to the Y47R-derived fibroblast cells. Investigating the 
FAST-1 expression pattern in NSCs showed a tendency to decrease in the YG8R 
and YG8sR NSCs cells, indicating that the FAST-1 expression may be cell type 
dependent. The analysis of FAST-1 expression in tissue samples derived from 
YG8R and YG8sR mice demonstrated that FAST-1 increased only in the brain and 
cerebellum tissues of the YG8R mouse model. Although YG8sR mice were derived 
from a founder YG8R mouse, they showed a different FAST-1 gene expression 
pattern from YG8R mice. FAST-1 expression was significantly decreased in selected 
YG8sR cells and tissues samples (Sandi and Pook, 2015). In this chapter, FAST-1 
expression was investigated in the brain, cerebellum and heart tissues of a new 
YG8sR-derived mouse model, designated YG8LR, containing approximately 410 
GAA repeats. Histone modifications at the FXN transgene were also studied using 
antibodies against the characteristic heterochromatin marker trimethylated histone 3 
lysine 9 (H3K9me3) and euchromatin marker acetylated histone 3 lysine 9 (H3K9ac). 
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5.2 Material and methods  
5.2.1 Quantification of FAST-1 and FXN mRNA levels in FRDA YAC transgenic 
mouse tissues 
Total RNA was extracted from 30mg frozen mouse tissue. Initially, tissue samples 
were homogenised in 1ml of Trizol by a plastic tissue grinder. The rest of the 
procedure was performed as described in section 3.2.5. As previously described in 
section 2.4.5 cDNA was synthesised using cloned AMV kit and qRT-PCR 
measurements were performed using Hprt as the endogenous control and two set of 
primers that recognize human FXN and FAST-1 cDNA. 
5.2.2 Chromatin immunoprecipitation (ChIP) analysis 
30mg of frozen cerebellum tissue was homogenised in cold PBS, in a final volume of 
1ml and ChIP was performed as previously described (section 2.4.14). For 
sonication, Bioruptor® Pico sonication System (Diagenode) was used to achieve the 
desired length of DNA fragments (100bp-500bp). Chromatin samples from mouse 
cerebellum tissue were sheared for 20 cycles of 30sec on / 30sec off, using 0.1 ml 
Bioruptor® Microtubes. Real-time PCR was performed in triplicate using a 
QuantStudio 7 Flex Real-Time PCR instrument (Applied Biosystems). Each qPCR 
reaction was carried out in triplicates in a 10µl reaction volume by using 2µl of the 
eluted immunoprecipitated DNA, 5µl of Fast SYBR Green Master Mix (Applied 
Biosystems) and 12.5pmol of each of the respective forward and reverse primers 
(Table 2.6). Relative quantification values were normalised to input and minus 
antibody samples, and finally determined in relation to a control region. 
 




5.3.1 Quantification of FXN and FAST-1 levels in 3-month old FRDA YAC 
transgenic mouse tissues 
FXN and FAST-1 expression levels were determined in brain, cerebellum and heart 
tissues from 3-month old YG8LR and Y47R mice. Y47R expression values were set 
as 100% and used as the basis for comparative expression results.  
Analysis of the 3-month old YG8LR mice (both male and female) compared to Y47R 
controls revealed that FXN mRNA levels reduced to 11% (P<0.001) in the brain, 7% 
(P<0.001) in the cerebellum, and 11% (P<0.001) in the heart tissues. In contrast, 
FAST-1 expression levels increased to 264% (P<0.001) in the brain, 320% 
(P<0.001) in the cerebellum, and 188% (P<0.001) in the heart tissues, (Figure 5.1). 
 
Figure 5.1: R elative FXN  and FA ST-1 expression  levels in brain , cerebellum and heart tissues of the 3-month o ld YG8LR males and f emales together.  
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To evaluate any potential gender-specific differences in FXN and FAST-1 mRNA 
expression levels, male and female groups were analysed separately. Analysis of 
the FXN and FAST-1 expression levels in the 3-month old male YG8LR mice 
revealed that FXN mRNA levels decreased to 15% (P<0.01) in the brain, 5 % 
(P<0.05) in the cerebellum, and 6% (P<0.01) in the heart tissues, while FAST-1 
expression increased to 320% (P<0.01) in the brain, 402 % (P<0.01) in the 
cerebellum, and 240% (P<0.001) in the heart tissues (Figure 5.2). 
 
Figure 5.2: R elative FXN  and FA ST-1 expression  levels in brain , cerebellum and heart tissues of the 3-month o ld YG8LR males.  
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The same pattern was detected in the 3-month old female YG8LR mice. Analysis of 
the female mice revealed decreased levels of FXN mRNA to 7% (P<0.001) in the 
brain, 8 % (P<0.001) in the cerebellum, and 16% (P<0.001) in the heart tissues, and 
increased levels of FAST-1 expression to 207% (P<0.05) in the brain, 238% 
(P<0.001) in the cerebellum, and 136% (P<0.05) in the heart tissues (Figure 5.3). 
 
Figure 5.3: R elative FXN  and FA ST-1 expression  levels in brain , cerebellum and heart tissues of the 3-month o ld YG8LR f emales.  
5.3.2 Quantification of FXN and FAST-1 levels in 9-month FRDA YAC 
transgenic mouse tissues 
Analysis of 9-month old YG8LR mice males and females together revealed that the 
FXN mRNA expression levels were significantly decreased in the brain, cerebellum 
and heart tissues to approximately 5% (P<0.05), 7% (P<0.01) and 8% (P<0.001) 
respectively, and FAST-1 expression increased to 172% (P<0.001), 271% (P<0.001) 
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and 177% (P<0.01) in the brain, cerebellum and heart tissues, respectively, 
compared to Y47R controls (Fig 5.4). 
 
Figure 5.4: R elative FXN  and FA ST-1 expression  levels in brain , cerebellum and heart tissues of the 9-month o ld YG8LR males and f emales together.  
Significant reduction in the FXN mRNA levels were also observed in the brain (5%, 
P<0.05), cerebellum (8%, P<0.001) and heart (3%, P<0.01) of the 9-month old 
YG8LR males. In addition, FAST-1 expression level increased to 172% (P<0.01) in 
the brain, 346% (P<0.01) in the cerebellum, and 236% (P<0.001) in the heart tissues 
compared to Y47R controls (Figure 5.5). 




Figure 5.5: R elative FXN  and FA ST-1 expression  levels in brain , cerebellum and heart tissues of the 9-month o ld YG8LR males.  
The same trend was also observed in the tissue of the 9-month old YG8LR females. 
The levels of FXN mRNA expression in the 9-month old YG8LR females were 
decreased to approximately 6% (P<0.001) in the brain, 6% (P<0.001) in the 
cerebellum, and 12% (P<0.001) in the heart tissues. In addition, The FAST-1 
expression levels were increased to 170% (P<0.05) in the brain, 196% (P<0.01) in 
the cerebellum, and 117% (P<0.05) in the heart tissues of the 9-month old YG8LR 
females compared with the Y47R control (Figure 5.6). 




Figure 5.6: R elative FXN  and FA ST-1 expression  levels in brain , cerebellum and heart tissues of the 9-month o ld YG8LR f emales.  
5.3.3 Investigation of histone modifications in YG8LR mice 
Since posttranslational histone modifications play an important role in FRDA, further 
investigations were carried out to assess levels of acetylation and trimethylation of 
histone H3 at lysine 9 in 9-month old cerebellum tissue from YG8LR mice. Histone 
modifications in cerebellum tissues from three male and three female YG8LR mice 
were investigated by ChIP analysis of the FXN promoter region as previously 
described in section 5.2.2. The immunoprecipitated DNA was amplified by qPCR and 
results were normalised to input and -Ab values were taken into account (see Table 
2.6 for primers used). All of the FXN promoter region values from the Y47R control 
Chapter 5: Quantification of FAST-1 expression in the YG8LR FRDA 
118 
 
mouse tissue were taken as 100%. The results showed a significant decrease in 
H3K9 acetylation and increase in H3K9 trimethylation in both male and female 
YG8LR mice (Figure 5.7). 
 











Recently, a new GAA repeat expanded mouse model, YG8LR, was derived from the 
natural breading of YG8sR YAC transgenic mice. The investigation of the molecular 
and behavioural phenotypes of this new mouse model revealed that features of 
FRDA patients are replicated in these mice. So far, most FAST-1 studies have been 
performed in cultured cells. Therefore, we were keen to investigate the FAST-1 
expression pattern in the most clinically relevant FRDA tissues, brain, cerebellum 
and heart tissues, but obtaining good quality autopsy tissues from FRDA patients is 
very difficult. To characterise our new human FRDA YAC transgenic mouse model, 
YG8LR, and to investigate the expression pattern of the human FAST-1 transcript 
across brain, cerebellum and heart tissues, we used a previously established robust 
qRT-PCR based method to quantify FAST-1 in YG8LR mouse tissues compared 
with Y47 control mouse tissues. To evaluate potential differences across time, we 
examined groups of mice that were 3-months and 9-months old. Similar decreases in 
the FXN expression and increases in the FAST-1 expression were identified at 3 
months and 9 months of age, suggesting that the molecular mechanisms are fixed 
by 3 months of age and do not vary thereafter. To evaluate any potential gender-
specific differences in FXN and FAST-1 mRNA expression levels, 3 male and 3 
female mice were analysed separately. Both male and female YG8LR mice express 
significantly less FXN mRNA in all three tissues, brain, cerebellum and heart, 
compared with control mice Y47R at both 3-months and 9-months of age. In 
contrast, FAST-1 levels were found to be significantly increased in YG8LR mice, 
specifically in the cerebellum tissue, in both males and females, at both 3-months 
and 9-months of age. These findings are in a good agreement with our previous 
results from FAST-1 studies in YG8R mouse models, but different to YG8sR FAST-1 
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studies. Previous studies in our lab identified significantly decreased levels of FAST-
1 expression in brain and cerebellum tissues of the YG8sR mice. On the other hand, 
YG8R mice tissues exhibited significantly increased levels of FAST-1 expression 
relative to control mice. Although YG8sR and YG8LR mice are both derived from an 
YG8R founder, YG8sR gene expression pattern was found to be different from 
YG8R and YG8LR mice, which may be due to the GAA repeat expansion differences 
in these groups of mice (Sandi and Pook, 2015).  
A plausible link between heterochromatin and antisense transcription in FRDA led us 
to investigate the acetylation and methylation of the conserved lysine residue of 
histone H3 in YG8LR cerebellum tissue in both male and female mice. Our promoter 
ChIP analysis in both male and female mouse cerebellum tissues showed increased 
trimethylation of H3K9, a hallmark of silenced chromatin, and H3K9 deacetylation in 
the FXN promoter region. These results are consistent with the findings of previous 
studies which also reported similar histone modifications in both FRDA human and 
YG8R mouse brain tissue (Al-Mahdawi et al., 2008). Our similar findings in cell 
models and mouse tissues indicate that FAST-1 has a definite role to play in FRDA 
disease mechanisms (De Biase et al., 2009). It also indicates that YG8LR mice are 
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FRDA is an autosomal recessive neurodegenerative disorder. It is the most common 
hereditary form of ataxia with an estimated prevalence of 1 in 50,000 in Caucasians. 
Most individuals with FRDA have a GAA repeat expansion within the first intron of 
the FXN gene in both alleles, which results in a severe deficiency of the encoded 
protein, frataxin. After almost 20 years since the identification of the genetic mutation 
underlying FRDA, the exact mechanisms by which GAA repeat expansions lead to 
the FXN gene silencing still cannot be explained. However, several potential 
mechanisms have been proposed based on experimental evidence. It has been 
suggested that abnormal triplex conformation, such as sticky DNA adopted by GAA 
repeat expansion and/or RNA.DNA hybrids, might impede the transcription of the 
FXN gene (Sakamoto et al., 2001a; Grabczyk et al., 2007). In addition, several 
previous studies of FRDA mouse models, human tissues and cells have highlighted 
the possibility of epigenetic changes being also either directly or indirectly involved in 
FXN gene silencing (Al-Mahdawi et al., 2008). Significant levels of histone 
deacetylation increased H3K9 methylation, significant enrichment of the repressive 
marks at the 5′UTR of the FXN gene, elevated levels of the non-coding RNA (FAST-
1) and hypermethylation of CpG regions upstream of the GAA repeat are the 
epigenetic changes that have been identified in FRDA (Herman et al., 2006; Greene 
et al., 2007; Kim et al., 2011). Enrichment of these repressive chromatin marks in the 
FRDA alleles provides evidence of the heterochromatin formation in the promoter 
region involving the critical +1 nucleosome and/or the first intron of the FXN gene. 
Bidichandani and colleagues showed that in FRDA patient-derived fibroblasts, the 
FXN Antisense Transcript (FAST-1) was expressed at higher levels. Previous in vitro 
studies in our lab also detected high levels of FAST-1 in the YG8R and YG22R- 
derived fibroblast cells (Sandi and Pook, 2015). In addition, it has been reported that 
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higher levels of FAST-1 were associated with the severe CTCF depletion and 
coincidentally heterochromatin formation in the 5′UTR of the FXN gene. It is 
important to note that FRDA cells do not have a generalized defect in CTCF binding 
(De Biase et al., 2009). Bidichandani and colleagues also reported that knocking 
down CTCF by siRNA in wild type fibroblasts resulted in high levels of FAST-1 and 
reduced FXN transcription. These results inspired us to investigate any possible role 
that FAST-1 might have in FRDA. Our results from overexpressing FAST-1 in three 
different non-FRDA cell lines demonstrated that FAST-1 can act in trans in a similar 
manner to the cis-acting FAST-1 overexpression that has previously been identified 
in FRDA fibroblasts. This mechanism of action, where an antisense RNA acts both in 
cis and trans and induces epigenetic silencing of its partner sense gene, has been 
reported for the p15 naturally occurring antisense transcript (Yu et al., 2008). We 
also observed that FAST-1 overexpressing HeLa cells had a reduced occupancy of 
CTCF, a decreased level of H3K9ac and increased levels of H3K9me3 at the 5′UTR 
of the FXN gene. This is interesting, because the start of FAST-1 transcription 
overlaps with the CTCF binding site in the 5′UTR of the FXN gene. The effects of 
FAST-1 overexpression on CTCF, H3K9ac and H3K9me3 at the FXN 5′UTR locus 
indicated a potential causative role for FAST-1 in FRDA, as opposed to the 
increased FAST-1 expression that is observed in FRDA merely being the passive 
result of loss of CTCF binding at the FXN 5′UTR. Thus, it is plausible that increased 
FAST-1 RNA molecules may displace CTCF from the FXN 5′UTR, resulting in 
heterochromatin formation and FXN gene silencing. The eviction of CTCF from its 
binding site by the increased transcription of an antisense non-coding RNA in 
chicken lysozyme gene has been reported by Bonifer and colleagues. They also 
demonstrated that CTCF eviction was associated with nucleosome repositioning 
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over the CTCF binding site, which prevented the re-association of CTCF with its 
binding site and resulted in a permanent eviction of CTCF/cohesin complex (Lefevre 
et al., 2008; Phillips and Corces, 2009). Their findings showed that non-coding RNA 
transcription is indispensable for chromatin remodelling and physical displacement of 
CTCF (Ong and Corces, 2008). CTCF is a highly-conserved zinc finger 
multifunctional chromatin protein, which is a key regulator of chromatin architecture 
and fundamental genomic processes, including insulation, X chromosome 
inactivation, gene activation, gene repression and chromatin looping (Bonev and 
Cavalli, 2016). It has been proposed that CTCF is involved in the boundary formation 
and the partitioning of distinct epigenetic domains. Loss of CTCF-dependent 
chromatin boundaries is a common event in epigenetic silencing of tumor suppressor 
genes. Results from TNR disease studies propose an important role for CTCF to 
establish the local chromatin structure at the repeats and restrict the repressive 
chromatin structure to the repeat region (Cho et al., 2005; Libby et al., 2008; De 
Biase et al., 2009). As mentioned earlier, we demonstrated that FAST-1 
overexpressing HeLa cells have a reduced occupancy of CTCF associated with 
H3K9m3 enrichment and decreased H3K9ac at the 5′UTR of the FXN gene. These 
results concur with other studies that show that the loss of CTCF is associated with 
the significant enrichment of H3K9me3 around CTCF binding sites and consequently 
causes chromatin compaction (Pavlaki et al., 2017). Based on these findings, it is 
plausible to speculate that FAST-1 overexpression may displace CTCF from the 
5′UTR of the FXN gene, which would result in secondary changes in chromatin 
structure that are incompatible with CTCF binding to DNA (Figure 6.1). 
 
Figure 6.1: R ole of FAST- 1 in FRDA. 
 




It has been demonstrated that embedding short GAA repeat expansions in a 
completely different sequence context induces heterochromatin formation and 
silencing of a linked reporter gene. It is well established that it is the intrinsic property 
of the expanded GAA repeat that causes heterochromatin formation and exert its 
gene silencing effect (Saveliev et al., 2003). It is not clear yet how GAA repeat 
expansion results in CTCF dislodgement. The expanded GAA repeat drives 
chromatin changes in intron 1 and this repeat-proximal heterochromatin spreads 
from the expanded GAA in intron 1 to the upstream regions of the FXN gene 
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encompassing the FXN promoter and CTCF binding site (Herman et al., 2006; 
Chutake et al., 2014a). One possibility is that the heterochromatin emanating from 
the expanded GAA repeat displaces CTCF from its binding site. Considering the 
reduced occupancy of CTCF, H3K9m3 enrichment and decreased H3K9ac levels -
hallmarks of heterochromatin formation - at the 5′UTR of the FXN gene in FAST-1 
overexpressing HeLa cells, it can be speculated that FAST-1 RNA, via subsequent 
heterochromatin, may indirectly displace CTCF. Indeed, several studies have 
reported that association of H3K9me3 heterochromatic mark with loss of CTCF 
binding is a common event in epigenetic silencing of cancer-related genes such as 
p16 and p53 (Witcher and Emerson, 2009; Soto-Reyes and Recillas-Targa, 2010). 
When the chromosomal boundaries are destabilised through dissociation of CTCF 
and long-range epigenetic organisations are lost, repressive chromatin can spread 
passively into the promoter region of the FXN gene and inhibit its transcription 
(Witcher and Emerson, 2009; De Biase et al., 2009). In addition, given the 
enrichment of CTCF at the border of lamina-associated domains (LADs), loss of 
CTCF can affect the position of genomic loci relative to the nuclear lamina (NL), a 
location with a generally repressive environment (Guelen et al., 2008; Yáñez-Cuna 
and van Steensel, 2017). With this in mind, it has been reported that the majority of 
expanded FXN alleles are positioned at the NL. Thus, CTCF loss and subsequent 
heterochromatin formation may contribute to FXN relocation to the NL and its 
repression (Silva et al., 2015). Recent studies suggest that CTCF has a contradictory 
function to its classical enhancer-blocker function. It has been proposed that CTCF 
can tether distant chromatin sites together, create a loop and physically bridge 
enhancer-promoter interaction (Oti et al., 2016; Hu and Tee, 2017). In addition, it has 
been demonstrated that gene looping plays an important role in restricting divergent 
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transcription of non-coding RNA. A protein factor, Ssu72, is found to be essential for 
gene looping and its mutation results in a significant increase in divergent non-
coding RNA production (Tan-Wong et al., 2012). The Ssu72 protein has been shown 
to bind to cohesin, a protein which strongly co-localises with CTCF (Kim et al., 2010). 
Based on these findings, it can be speculated that CTCF may facilitate enhancer-
promoter interactions at the 5′UTR of the FXN gene to drive the FXN expression. 
FAST-1 overexpression and resultant local depletion of CTCF could abolish this 
CTCF-mediated enhancer-promoter interaction and consequently reduce FXN gene 
expression. In addition, CTCF can directly interact with the largest subunit of RNA 
pol II (LS Pol II) (Chernukhin et al., 2007). It can also enhance pausing of RNA pol II 
and facilitate remodelling of the chromatin and interact with positive elongation factor 
B to facilitate efficient transcription elongation (Laitem et al., 2015). It has been 
reported that, in FRDA cell lines, the RNA pol II level is decreased throughout the 
FXN gene but it remains unchanged in the promoter region (Kim et al., 2011). 
Transcription in the antisense direction is more likely to terminate due to RNA pol II 
stalling (Bornelöv et al., 2015). Therefore, loss of CTCF in FRDA may contribute to 
disrupted transcription and repressive chromatin structure. If we consider non-coding 
transcript to be transcribed in an enhancer-independent manner, then loss of CTCF 
may promote FAST-1 transcription in FRDA. Non-coding RNAs have also been 
found to interact with transcription factors and regulate local gene expression. The 
growth arrest-specific 5 (Gas5) gene encodes a non-coding RNA that can interact 
with DNA binding domain of the glucocorticoid receptor (GR) and suppress 
glucocorticoid-activated genes. Measuring occupancy changes of transcription factor 
GR following overexpression of Gas5 demonstrated that GR was depleted at its 
target promoters leading to decrease in GR-induced mRNA expression (Kino et al., 
Chapter 6: General discussion 
128 
 
2010; Hudson and Ortlund, 2014). Two transcription factors, SRF and TFAP2, have 
been found to regulate expression of the FXN gene. They bind directly to a region 
that is located close to the start of FAST-1 antisense transcript (Li et al., 2010). 
Therefore, it is possible that FAST-1 acts as a decoy, reducing the availability of 
these transcription factors required for the FXN gene transcription. 
To investigate the molecular mechanisms that may be involved in reducing FXN 
mRNA and protein level in FAST-1 overexpressing cells, we performed 
MethylScreen analysis to determine the general DNA methylation status (5mC and 
5hmC) at the CpG sites U6 and U11 of the FXN upstream GAA intron 1 region. Our 
result revealed that FAST-1 overexpressing cells exhibited an FRDA-like increased 
DNA methylation profile at these CpG sites. Previous studies in our lab showed that 
the majority of the methylated DNA in the FXN upstream GAA repeat region 
comprises 5hmC rather than 5mC, and 5hmC is known to promote DNA 
demethylation (Guo et al., 2011). Thus, 5hmC levels can be considered as an 
indicator of DNA demethylation progression. In contrast, no alterations in the DNA 
methylation status have previously been detected at the CTCF binding site in 
the FXN 5′UTR region of FRDA cells or tissues (Greene et al., 2007; Al-Mahdawi et 
al., 2008). Furthermore, it has been reported that a natural occurring antisense 
transcript could induce DNA demethylation, and its overexpression dramatically 
abolishes DNA methylation (Imamura et al., 2004). Therefore, one can postulate that 
increased levels of FAST-1 might explain the reduced DNA methylation status at the 
CTCF binding site in the FXN 5′UTR, which is concurrent with FXN gene silencing. 
Antisense transcription is a very common phenomenon in mammalian 
transcriptomes. Although natural antisense transcripts can show mRNA-like 
characteristics such as having a poly A tail and a 5′ cap structure, the function of 
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these transcripts is not well understood (Villegas and Zaphiropoulos, 2015). 
Experimental evidence suggests that non-coding RNA can influence gene 
expression by recruiting chromatin remodeling complexes to specific alleles and 
mediating heterochromatin formation and gene silencing. It has been shown that the 
PRC2 complex associates with almost 3000 NATs in mouse embryonic stem cells 
(Zhao et al., 2010; Halley et al., 2013). Indeed, antisense transcripts can act as 
scaffolds or directly recruit PRC2 to chromatin in cis and trans manners to induce 
trimethylation of H3K27 and consequently establish a silent chromatin state. 
According to this mechanism, even a relatively low abundance of antisense 
transcript can mediate transcriptional repression (Holoch and Moazed, 2015). In 
addition, recent studies suggest that there is a cooperative mechanism between 
H3K27 and H3K9 methylation marks, where H3K9me3 can crosstalk with the 
Polycomb H3K27me3 modification to cooperate in gene silencing. Indeed, 
H3K27me3-bound PRC2 stabilizes H3K9me3-anchored HP1 and reinforces 
heterochromatin formation and ensuing gene repression. Significant enrichment of 
H3K9 and H3K27 methylation and HP1 has been reported at the FXN locus of 
FRDA-derived fibroblast cells. Here in FAST-1 overexpressing HeLa cells, we also 
identified significant enrichment of H3K9me3 at the 5′UTR of the FXN gene. In 
addition, it has been reported that 5hmc and H3K27me3 are tightly correlated across 
a variety of somatic tissues and high levels of both marks have been identified in 
FRDA (Haffner et al., 2013). Moreover, knowing that genomic repeats are targets of 
Polycomb complexes and repeat sequences might provide a binding platform for 
polycomb group proteins, it is conceivable to speculate that the expanded GAA 
repeat and high levels of FAST-1 either directly or indirectly recruit PRC2, and 
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through a cooperative mechanism dictate heterochromatin formation and FXN gene 
silencing in FRDA (Leeb et al., 2010; Al-Mahdawi et al., 2013).  
To further investigate the possible role of FAST-1 in FXN gene expression, FAST-1 
was knocked down using lentiviral shRNA particles. Our results showed that 
knocking down FAST-1 in FRDA fibroblast cells increases FXN gene expression, but 
not to the level of normal cells (Figure 6.1). Therefore, it can be concluded that since 
FAST-1 is associated with epigenetic repression of the FXN gene, inhibition of 
FAST-1 may be an approach to increase the FXN transcripts and stimulate 
subsequent protein expression. Considering the nature of NATs and the fact that 
many currently available drugs would not affect the activity of non-coding RNA 
molecules, developing new methods to disrupt the function of NATs seems 
necessary. Knocking down NATs using siRNA, using oligonucleotides containing 
locked nucleic acid modifications (AntagoNAT) or by blocking their interaction with 
their associated histone modifying enzymes, are the potential methods for targeting 
NATs (Halley et al., 2013). Using an AntagoNAT strategy to knock down the BDNF 
(brain-derived neurotrophic factor) NAT has been shown to have promising results in 
both cell cultures and in vivo. Knocking down this antisense transcript, considerably 
increased sense mRNA and protein expression and modified chromatin marks 
(Modarresi et al., 2012a). One of the main advantages of targeting NATs is their 
locus-specific gene upregulation effects. However, there are formidable biological 
barriers that need to be addressed. These include increasing the resistance to 
nuclease degradation, reducing the base pair length of the oligonucleotide to 
increase cellular uptake and decreasing the toxicity effects whilst still maintaining 
high binding affinity for the target nucleic acid (Wahlestedt, 2013).  
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In conclusion, a full-length FAST-1 transcript with a total length of 523bp in size was 
previously identified in our lab. Mapping the 3′ and 5′ ends of FAST-1 transcript onto 
the genome precisely localised them to nucleotides -359 and 164 of the FXN gene, 
respectively. Of particular interest is the fact that the 5′ end at position 164 coincides 
with a known CTCF binding site. A poly (A) signal was also identified in the FAST-1 
sequence at nucleotide positions of -341 to -346 (Sandi and Pook, 2015). In this 
research project, I aimed to investigate the potential role of FXN antisense transcript-
1 (FAST-1) in FRDA. Therefore, I first overexpressed FAST-1 in HEK293, HeLa and 
fibroblast cell lines and I observed a consistent decrease in FXN expression in each 
cell type compared to control cells. I also identified a positive correlation between 
FAST-1 copy number and FAST-1 expression and a negative correlation between 
FAST-1 expression and FXN expression. Additionally, I found that FAST-1 
overexpression is associated with CTCF depletion and heterochromatin formation at 
the 5′UTR of the FXN gene. Furthermore, I performed short hairpin RNA (shRNA) 
knock down of FAST-1 in FRDA fibroblasts, detecting significantly increased FXN 
expression, but not to the same levels as the control fibroblasts. Studying clinically 
relevant FRDA tissues from GAA repeat expansion-containing FXN transgenic mice 
revealed that elevated levels of FAST-1 were associated with increased histone 
marks for silenced chromatin and decreased FXN expression. Overall, our results 
suggest a role for FAST-1 in the epigenetic regulation of FXN gene expression 
(Figure 6.1). Further studies are required to fully understand the details of this 
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